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ABSTRACT 
Findings released from recent pivotal clinical trials on hormone therapy (HT) 
benefits and risks have stimulated a growing trend towards lower doses and earlier 
discontinuation of HT for menopausal women.  Yet, there is little knowledge regarding 
women’s personal experiences with the resultant earlier and possibly abrupt withdrawal 
of HT. The purpose of this study was to explore postmenopausal women’s vasomotor 
symptom experiences after discontinuing HT.   
The data for this study was collected from menopausal women who discontinued 
HT. The study questionnaire was created through an extensive review of the literature as 
well as an expert panel review. The questionnaire was also piloted with a small group of 
women prior to its use in this study. 
Data analysis consisted of descriptive analysis with means and standard 
deviations and/or frequency distributions with percentages for demographic data, health 
behaviors, factors influencing HT decisions, use of CAM and perceived efficacy. Chi-
square analysis, Spearman Rho correlation, and logistic regression analysis were 
conducted for contextual factors and vasomotor symptom experiences. A McNemar test 
 viii
was performed to assess within group differences for vasomotor symptoms experiences 
pre and post HT. 
Questionnaires were received from 563 menopausal women throughout the 
United States. This study revealed that 80% of participants experienced vasomotor 
symptoms after discontinuing HT. The most common predictors which accounted for 
only 13% of variance in the occurrence of vasomotor symptoms were younger age, type 
of menopause and the occurrence of vasomotor symptoms prior to initiation of HT. 
Of the 563 women participating in the study, less than half reported the use of 
CAM to treat reemerging vasomotor symptoms. For the most part, less than half of the 
women felt their treatment choices were helpful in relieving their reemerging vasomotor 
symptoms 
Because a woman’s experience of menopause can be highly individualized, an 
adaptation of Bronfenbrenner's ecological theory was used guide this exploratory study.  
The study findings supported the usefulness of the adaptation of Bronfenbrenner’s 
ecological theory as a model through which to view the vasomotor experiences of 
menopausal women who have discontinued HT.  
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Chapter One: Introduction and Theoretical Framework 
OVERVIEW 
Natural menopause is a universal biologic event for all women who live long 
enough and have not experienced some type of pathology or medical/surgical 
intervention altering the natural process. Menopause can be viewed from two different 
perspectives, the biomedical perspective, in which menopause is viewed as a disease state 
characterized by estrogen deficiency or from a developmental perspective in which 
menopause is considered a natural part of a woman’s life but experienced differently by 
women of varying backgrounds.  
The biomedical paradigm began in the 1930’s with the development of an 
etiologic theoretical framework for female sexual functioning introduced by researchers 
in the field of sex endocrinology and the discovery of sex hormones (Formanek, 1990). 
The medicalization of menopause emerged along with the introduction of 
diethylstilbestrol (DES) a synthetic estrogen introduced in 1941 to treat menopausal 
symptoms. At this time estrogen was approved by the US Food and Drug Administration 
(FDA) specifically for treatment of vasomotor symptoms (i.e.: hot flashes, night sweats) 
and urogenital atrophy brought about by declining endogenous estrogen levels 
experienced during menopause (Formanek, 1990; Rousseau, 2001). Vasomotor 
symptoms were and still are the most common symptom for which menopausal women 
seek relief from (Lobo, Kelsey & Marcus, 2000; Speroff & Fritz, 2005). Many women 
have indeed benefited from estrogen therapy to relieve symptoms experienced during 
menopause.  
The use of estrogen has waxed and waned over the years in response to various 
historical events. A popular text published in the 1966, “Feminine Forever” by R. A. 
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Wilson heralded the news to lay women that menopause was a deficiency disease state 
and they should not have to suffer the consequences related to the decline in endogenous 
estrogen levels. Wilson (1966) believed that exogenous estrogen could be taken to ‘cure’ 
menopause and keep women forever vibrant and healthy. At this time estrogen was 
beginning to be prescribed as a hormone replacement therapy (HRT) by a few clinicians 
for menopause symptoms as well as other purported health benefits that were outside the 
prescribing guidelines (off label) set by the FDA in 1942.  Note, to provide consistency 
of terms, from this point on HRT will be referred to as hormone therapy (HT) as is now 
currently recommended (FDA, 2003; Sturdee & MacLennan, 2003). 
This trend of increasing HT use quickly declined in the 1970s because of the 
emergence of endometrial cancer. Endometrial cancer was found to be associated with 
the use of estrogen that was unopposed by a progestational agent (Antunes, 1979; 
Kaunitz, 1980). Soon after, with the addition of a progestational agent to the HT regimen 
to oppose the proliferative effects of estrogen on the endometrial tissue of the uterus, 
protecting it from endometrial cancer, HT use again began to rise once more (Rousseau, 
2001; Genazzani, 2002).  
The basic biomedical tenets with regard to the phenomenon of menopause as a 
deficiency disease and its treatment remained remarkably similar throughout the next few 
decades. In the 1980s and 90s, HT not only was recommended for vasomotor symptoms 
it became a panacea for the maintenance of a menopausal woman’s health.  During this 
time there was yet again a rise in the use of HT, especially in off label prescribing of HT 
for health promotion and disease prevention. During this time epidemiologic evidence 
began to emerge supporting the use of estrogen to reduce the risk chronic and other 
medical conditions such as osteoporosis, coronary heart disease (CHD), colon cancer and 
cognitive decline, of which  CHD was the most prominent (Pinn, 2005; Rousseau, 2001).  
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In recent years evidenced based medicine (EBM) has emerged in which clinical 
practice is to be guided by high level clinical research. High level research should include 
the gold standard of a randomized, placebo controlled clinical trial, powered sufficiently 
to yield the most accurate findings. For HT, there are a few benefits that are clearly 
supported by EBM. These benefits include the relief of vasomotor (Nelson, 2004) and 
urogenital symptoms (Willhite & O'Connell, 2001) as well as the role of HT in the 
prevention of osteoporosis (Keating, Manassiev, & Stevenson, 2000). Although 
randomized, placebo controlled trials were lacking at this time, there were epidemiologic 
data and empirical evidence that provided some evidence that HT may indeed reduce the 
risk of heart disease in women (Bush, 1990; Derby, 2000; Grady, et al., 1992; Psaty, 
Heckbert & Atkins, 1994; Sidney, Petitti & Quesenberry, 1997; Stampfer & 
Colditz,1991) 
The most common risks of HT known today were well known at that time as well. 
These known risks that were associated with the use of HT included an increased risk of 
venous thrombembolic events (VTE) and arterial strokes.  Endometrial cancer was a 
known risk, but there was clear clinical evidence indicating that estrogen when opposed 
by a progestational agent not only decreased the risk of endometrial cancer, but indeed 
reduced the risk lower than that of a woman who did not take HT at all (Genazzani, 2002; 
Speroff & Fritz, 2005). Clinical trials and epidemiologic data with regard to breast cancer 
risk associated with HT demonstrated conflicting results with a trend towards only a mild 
increased risk for women who were at higher risk for breast cancer (Genazzani, 2002; 
Speroff & Fritz, 2005) 
Recently, released findings from three recent key clinical trials on the effects of 
HT, the Heart and Estrogen/progestin Replacement Study (HERS) (Hulley, et al 1998), 
the follow-up non-cardiovascular disease outcomes during 6.8 years of hormone therapy: 
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the Heart and Estrogen/progestin Replacement Study follow-up (HERS II) (Grady, et al., 
2002), and the Women’s Health Initiative (WHI) (Rossouw, et al, 2002) have provided 
evidence based clinical guidance for health care providers with regard to the risks and 
benefits with the administration of exogenous hormones. The findings from these pivotal 
clinical trials, although controversial, have nudged the motion of the pendulum back 
toward the view of menopause as a natural life event experienced uniquely by each 
woman. For now routine use of HT for varied health conditions has turned to a more 
judicious individualized treatment approach for women. In response to this new data and 
to provide guidance for clinicians, an independent panel prepared and released the 
National Institute of Health (NIH) consensus statement on the “Management of 
Menopause-related Symptoms” in March of 2005. This report provides a review of the 
literature of EBM for the management of menopause symptoms as well as a 
recommendation to demedicalize menopause (National Institute of Health [NIH], 2005). 
The U.S. Food and Drug Administration (FDA) also recommends that estrogens should 
only be prescribed for the treatment of menopausal vasomotor and urogenital symptoms 
at the lowest possible dose for the shortest time possible (U.S. Food and Drug 
Administration (2004).  
In response to these historical events/pivotal clinical trials clinical practice 
patterns now reflect that there has been a decrease in new prescriptions for hormones as 
well as a noted decrease in the dosage of current prescriptions for hormone therapy. 
(Blümel, et al., 2004; Hersh, Stefanick & Stafford, 2004). Although, there is 
documentation of a growing trend towards earlier discontinue hormone therapy there is 
little information about how this trend will affect women’s menopausal experiences. 
Given that HT was once considered very beneficial for women and that they would likely 
continue with therapy for most of their postmenopausal life, information is lacking about 
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women’s personal experiences related to withdrawal of HT with this abrupt change in 
clinical practice patterns. Thus, future research studies are needed to explore, assess and 
articulate the experiences of diverse groups of menopausal women who have chosen to 
discontinue hormone therapy.  
PURPOSE 
The primary purpose of this study was to explore postmenopausal women’s 
vasomotor symptom experiences after discontinuing HT.  The influence of contextual 
factors (i.e.: weight, smoking, ethnicity, and type of menopause) on the vasomotor 
experiences of post-hormone therapy postmenopausal women was examined and 
compared with factors that have been associated with vasomotor symptom experiences 
prior to initiation of hormone therapy. The factors that influenced discontinuation of 
hormone therapy were also explored.  In addition, this study assessed the use of 
alternative medical treatments and complementary and alternative medicine (CAM) 
therapies women have undertaken specifically to treat vasomotor symptoms as well the 
women’s perceived effectiveness of these therapies.  
BACKGROUND AND SIGNIFICANCE 
Life expectancy has increased dramatically over the past 100 years, and currently 
the average life expectancy at birth is 77 years of age in the United States. In addition to 
the increase in life expectancy, the population of older Americans has grown as well.  In 
fact the youngest members of the seventy-five million American baby boomers born 
between 1946 and 1964 are now over the age of 40 (National Center for Health Statistics, 
Data Warehouse on Trends in Health and Aging). 
It is estimated that in July 2004, there were 32,759,100 women who fell between 
40 to 54 years of age (U.S. Census Bureau, Population Division, 2004). The average age 
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of natural menopause in the United States is between 50-52 years old (Speroff & Fritz, 
2005), thus a substantial number of women have or will begin to experience menopause. 
Women experiencing menopause with the increased life expectancy in the last century, 
will live over a third of their lives postmenopause.  
Clearly, the experiences of a population cohort this large cannot be ignored. For 
many women, menopausal vasomotor symptoms can impact their perception of health 
and influence the types of health behaviors they will adopt. Health behaviors may include 
the use of non hormonal alternative medications (i.e.: antidepressants and antiepileptics) 
as well as CAM therapies such as acupuncture, yoga, and the use of botanicals and 
dietary supplements to reduce vasomotor symptoms associated with menopause. 
Illuminating the needs of this large group of women will provide valuable information 
that will help to guide future research in evaluating the safety and efficacy of alternative 
therapies.   
Vasomotor Symptoms 
The term vasomotor symptoms describes a collection of menopausal symptoms 
such hot flashes, hot flushes and night sweats. A hot flash or hot flush is a sudden feeling 
of warmth and often a breakout of sweating usually confined to the chest, neck, face and 
head (Freedman, 1998, 2001; Speroff & Fritz, 2005). There is an intense feeling of heat 
that often initiates in the chest area and spreads to the face head and neck. When hot 
flashes occur at night, the breakout of profuse sweating which is often referred to as night 
sweats can disrupt sleep patterns (Friedman, 2001; Speroff & Fritz, 2005). Although 
many women may progress through menopausal transition without any difficulty, the 
majority of women will experience vasomotor symptoms. It is estimated that 
approximately 60 to 85% of women experience hot flashes during the peri- and 
postmenopause. (Feldman, Voda & Gronseth, 1985; Kronenberg, F., 1994; McKinlay, 
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Brambrilla, & Posner, 1992; Neugarten & Kraines, 1965; Stearns, et al., 2002). For 
women who have had surgical menopause, the number of women experiencing 
vasomotor symptoms is much higher at nearly 90% (Chakravarti, Collins, Newton, Orom 
& Studd, 1977; Feldman, Voda, & Gronseth, 1985).  Studies have found that between 30 
and 60% of women will report that symptoms are severe enough to disrupt activities of 
daily life, interfere with restful sleep and warrant treatment (Gold, et al, 2000; Freedman 
& Roehrs, 2004; Fuh, Wang, Lee, Lu, & Juang, 2003; Oldenhave, Jaszmann, Haspells & 
Everserd, 1993). It has been shown in various studies that women who have hot flashes 
will continue to have symptoms for an average of 1-2 years, up to 4-5 years or longer in 
some women (Kronenberg, 1994; Speroff & Fritz, 2005). Culture and ethnicity have been 
shown to play a part in the symptom reporting and experience (Avis, et al, 2001; Beyene, 
1989; Lock & Kaufert, 2001), as well as lifestyle and demographic factors (Gold, et al, 
2000; Randolph, et al., 2003) and even weight (Randolph, et al., 2003). 
Despite the fact that vasomotor symptoms are very common among women, the 
etiology of vasomotor symptoms is still not clearly understood. Nor, are hot flashes 
exclusively experienced by menopausal women, men can experience them as well. 
Conditions other than menopause can also produce flushing such as emotional flushing, 
exposure to heat, alcohol or monosodium glutamate consumption, carcinoid syndrome, 
systemic mast cell disease, pheochromocytoma, medullary carcinoma of the thyroid, 
pancreatic islet-cell tumors, renal cell carcinoma, hypertension, hyperthyroidism, 
neurological flushing, and spinal cord injury (Wilkin, 1981).  
Hot flashes associated with menopause were originally thought to be related 
simply to the drop in endogenous estrogen during menopause. This theory is supported in 
part by the overwhelming evidence showing that treatment with exogenous estrogens will 
almost always relieve hot flashes (MacLennan, Broadbent, Lester, S., & Moore, 2004). 
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Understanding these etiologies have led to additional clinical trials to investigate 
alternative treatment modalities to relieve menopausal symptoms. This is an important 
area of research as more women discontinue estrogen therapies in light of recent 
historical events. It is unknown whether vasomotor symptoms experienced after 
discontinuation of HT are in fact the same as those experienced prior to hormone 
initiation.  
Hormone Therapy Discontinuation Experiences 
Recent historical studies have provided more evidenced-based information about 
HT risks and benefits. Contrary to expectations, these studies did not provide evidence to 
support the use of HT for prevention of some chronic health conditions. These studies 
have initiated a trend towards a shorter period of use of HT for the treatment of 
vasomotor symptoms. Driven by this new evidence more women will likely personally 
opt out or will be guided by their health care providers to stop HT earlier than originally 
planned. At present, little is known about the potential symptom experiences of 
menopausal women with earlier and possibly abrupt discontinuation of HT. Only three 
studies were located that assessed the experiences of women after the discontinuation of 
HT.  Two of the studies were published post WHI study and one prior.  
In the one study published prior to the release of WHI findings, the researchers 
(Hammar, et al., 1999) assessed whether vasomotor symptoms might be induced 
specifically in menopausal women who had never previously experienced vasomotor 
symptoms when they were given HT for 14 weeks, and then abruptly taken off. Forty 
menopausal women, who had reported that they had no history of vasomotor symptoms, 
were not on HT and were not at an increase risk for thrombembolic events or malignant 
diseases were included in the study. Women who had a hysterectomy were excluded from 
this study. The women were randomized to either a treatment group (17β-estradiol 
 9
50μ/day for 12 weeks, followed by a progesterone withdrawal on weeks 13 and 14) or to 
the placebo group. Thirty eight women completed the study. The researchers found that 
there was no report of vasomotor symptoms in the either the treatment or placebo group 
after the 14 week trial. This study suggests that the abrupt withdrawal of estrogen does 
not trigger vasomotor symptoms. These findings although only apply to those women 
who had not previously experienced vasomotor symptoms. The authors did not report 
demographic information on race/ethnicity or socioeconomic status. 
Grady, Ettinger, Tosteson, Pressman, & Macer (2003) published the first study 
after the release of data from WHI study, investigators. The primary purpose of this study 
was to identify certain characteristics in women that would make it more difficult to 
discontinue HT.  The authors surveyed a random sample (N=377) from a large health 
plan database, the Kaiser Foundation Health Plan.  Through phone interviews with 
trained interviewers, the authors found that approximately 26% (N=97) of the women 
who had attempted discontinuation of HT had difficulty in doing so because of 
withdrawal symptoms and resumed the use of HT. Contextual factors identified that were 
most highly associated with the inability to stop HT were hysterectomy and duration of 
hormone use of over 10 years. The authors found no significant association of symptoms 
with contextual factors of age, ethnicity, education, BMI and smoking.  
Grady and colleagues (2003) also found that tapering off of HT was no more 
affective than stopping abruptly in preventing the occurrence of vasomotor symptoms, 
although data on the specific method of tapering was not collected. The participants in 
this study were primarily White (77%) and well educated with 43% having earned a basic 
college degree or better.  
In a cross-sectional survey Ockene and colleagues (2005) explored the menopause 
symptom experiences of women who had recently participated in the estrogen and 
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progestin treatment arm of the WHI study. The study survey was sent approximately 8-12 
months after the study was stopped to women who were still on HT prior to the 
discontinuation of the WHI study. All women who were on study drug (HT) when the 
WHI study was stopped were instructed to discontinue it. The authors reported that the 
respondents compared to the non-respondents of this survey were more likely to be 
White, older, married, with a high school education or better.  
The authors found that the strongest determinant of occurrence of vasomotor 
symptoms after discontinuation of HT was the presence of vasomotor symptoms at 
baseline even after adjusting for age, BMI, alcohol and tobacco use. Other adjusted 
contextual factors that increased the likelihood of vasomotor symptoms included HT use 
before the study and current smoking. Similar to the findings of Hammar, et al (2003), 
the authors also found that women who did not have vasomotor symptoms prior to 
treatment were less likely to experience vasomotor symptoms even after abrupt 
withdrawal of HT.  
Those participants who resumed HT on their own were asked why they did so. 
The most common reasons for restarting HT was for the relief of vasomotor symptoms, 
to feel better, and on the advice of their personal clinician.  Of those participants who did 
not resume therapy, the authors explored lifestyle and medical management modalities 
that were undertaken for symptom relief. Fifty percent of the women reported the use of 
at least one management strategy. The most common management strategy was the use of 
lifestyle changes such as drinking more fluids. The participants in this study were 
primarily White (87%), well educated with nearly 37% with a basic college degree or 
better. Less than 5% did not finish high school in this sample (Ockene, et al., 2005).  
Collectively these studies illustrate the varied experiences of menopausal women 
who were directed to discontinue HT. In 2 of the studies (Hammar, et al, 1999; Ockene, 
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et al, 2005) the women were clearly instructed to discontinue HT, whereas in the study by 
Grady, et al (2003) the women shared a variety of reasons for why they discontinued. 
Yet, more information about discontinuation experiences is needed about the women who 
are not typically represented in clinical trials (i.e.: Hammar, et al., 1999; Ockene, et al., 
2005) or within a Health Maintenance Organization group (Grady, et al., 2003).  
The current study builds upon these aforementioned studies through a 
retrospective exploration of postmenopausal women’s vasomotor symptom experiences 
after discontinuing HT. The women in this study stopped HT on their own for a variety of 
reasons but were not asked to discontinue HT as part the study requirement (i.e. Hammar, 
et al, 1999; Ockene, et al., 2005). Similar to Ockene, et al, (2005) this study also assessed 
the use alternative medical treatments and complementary and alternative medicine 
(CAM) therapies women have undertaken specifically to treat vasomotor symptoms as 
well the women’s perceived effectiveness of these therapies.  
RESEARCH AIMS 
1. To identify factors menopausal women report that influenced their 
decisions to discontinue HT.  
2. To explore the vasomotor symptom occurrences in menopausal women 
who have discontinued hormone therapy. 
3. To explore the relationship between contextual factors and vasomotor 
symptoms after the discontinuation of hormone therapy.  
4. To identify alternative treatments that women have undertaken to treat 
menopause symptoms and their perceived efficacy. 
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THEORETICAL FRAMEWORK 
Menopause is a term used to describe the end of a woman’s fertile years which is 
signaled by the cessation of menstruation. In Western cultures, the predominant 
menopause discourse arises from the biomedical model and is considered a pathological 
condition. The universality of the reproductive senescence among aging women lends 
itself to the belief that the menopausal experience is universal in all women. Over the last 
few decades, as has been discussed earlier in this proposal, menopausal discourse 
continues to be a biomedical construct despite the trend towards use of HT only for the 
treatment of vasomotor symptoms.  
Each woman experiences menopause through the lens of her personal experiences 
and interactions with others.  An adaptation of Bronfenbrenner's ecological theory serves 
as a useful model for viewing these varied menopause experiences (Bronfenbrenner, 
1979, 1986). There is no universal characterization of menopause and a woman’s 
experiences are affected by all aspects of her life. Any theoretical framework used to 
guide culturally sensitive research exploring women’s experiences during withdrawal 
from HT must be able to provide a multidimensional structure. Human Ecology is an 
interdisciplinary applied field that utilizes a holistic approach to solving problems and 
enhancing human potential within the context of family, home, community and state. An 
ecological theoretical framework emerging from the study of human developmental 
ecology can help to assess the multidimensional aspects of individual health and well 
being of the individual within the context their environment. Through this holistic 
assessment of the individual there is an opportunity to develop health promotion, 
education and disease prevention interventions within the individual and the community 
to achieve sustainable positive health behavior (Bent, 2003; Bronfenbrenner, 1979, 1986; 
Bronfenbrenner & Ceci, 1994; Cohen, Schribner & Farley, 2000; Dan, 1994; Elliott, 
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Taylor, Cameron & Schabas, 1998; Formanek, 1990; Green, Richard & Potvin, 1996, 
Gryzwacz & Fuqua, 2000; Karpati, Galea, Awerbuch & Levins, 2002; Richard, Potvin, 
Kishchuk, Prlic & Green, 1996; Stokols, 1996, 2000). In addition, findings from research 
that is conducted within an ecological framework can serve as catalysts and provide 
support for changes in community-specific health care practices as well as the initiation 
of pertinent health policies at various governmental levels which have the potential to 
positively impact health outcomes (Green, et al., 1996; Richard, et al., 1996; Ruffing-
Rahal, 1989, 1993, 1998; Stokols, 1996, 2000). 
The developmental human ecological theoretical framework/model offered by 
Urie Bronfenbrenner (Bronfenbrenner, 1979) builds upon the work of Kurt Lewin who 
has suggested that in order to change behavior, the environment must be changed as well 
(in Bronfenbrenner, 1979).  Bronfenbrenner's (1979, 1986) writings on the ecological 
approach to human development include the interaction between an individual and the 
social and physical environment.  
Bronfenbrenner (1979) asserts that the ecological framework of human 
development involves the interaction of the individual, changes in their immediate 
environment as well as a larger environment beyond the immediate environment within 
which the individual is located. The individual is not a fixed entity within the 
environment, but is a dynamic force that has impact on the environment within which the 
individual resides as well. The environment in turn also affects the individual in a process 
of “mutual accommodation” (Bronfenbrenner, 1979, p.22) 
The ecological model consists of progressively enlarging spheres representing 
individual and social systems (see figure 1) (Bronfenbrenner, 1979).  The central sphere, 
the microsystem, represents the systems and characteristics that compose an individual 
Microsystems consist of an individual’s genetic make up (ethnicity, race, age at 
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menopause), personal characteristics (weight, height, general health, smoking, alcohol or 
drug use) as well as a place or setting where individual is engaged in close face-to-face 
interactions with others, such as the home, extended family, work or school settings. 
Interrelations among microsystems are called mesosystems. The mesosystem, the next 
larger sphere encompassing the microsystem, provides positive ties among the 
microsystems benefiting the individual. Mesosystems are those settings in which the 
individual interacts in more than one setting either alone or through linkage of a third 
party and/or by the “intersetting” of knowledge through written communications such as 
pamphlets and books. The mesosystem could include social networks, clubs, churches, 
neighborhood and other peer groups.  Additional systems include exosystems (i.e., 
influential external contexts, such as spouse’s work settings or personal work settings, 
health care provider or clinic). And, finally, macrosystems (i.e., broader cultural and 
historical influences such as consensus statements following the WHI and HERS trials) in 
which all the other systems are embedded (Bronfenbrenner, 1979). 
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Ecological Model as a Guide for Women’s Health Research 
Given the vast differences of women’s menopausal experiences, the ecological 
framework was chosen to help guide this research. McBride and McBride (1981) set forth 
seven criteria that should be embraced in theoretical frameworks used to guide women’s 
health research. These criteria include: 1) that women be included as subjects in research; 
2) that socio-cultural factors that impact health should be included in the investigation, 3) 
investigations should include how women are treated within the health care system (i.e. 
HT prescribing practices, acknowledgement of menopausal vasomotor symptoms, 
chronic disease risk recognition and prevention); 4) should acknowledge that male 
behavior is not necessarily the norm for women; 5) acknowledges that women’s health 
concerns merit serious investigation (i.e. vasomotor symptoms); 6) should investigate all 
women’s issues, not just reproductive concerns; and finally 7) appreciate that women’s 
transitions should be seen as normal as opposed to as a pathological process . 
Andrist and MacPherson (2001) outlined common valuable characteristics 
important for research for women’s health. Characteristics include that the 1) research is 
grounded in the lived experience of the woman; 2) the researcher is in relation with the 
subject; 3) there is reflexivity and finally 4) that the research is useful and valuable to 
women.  
Timmerman (1999) discusses theoretical underpinnings that provide a guide for 
women’s health research studies that utilize quantitative measures. Timmerman (1999) 
addresses the importance of describing the lived experience of women in context, the 
acknowledgement and identification of possible personal biases of the researcher and its 
impact on the investigation, the importance of health as the focus of research with the 
avoidance of transforming normal processes into disease processes and finally, providing 
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feedback to the participants as well as making the process of study involvement 
convenient for the participants.  
Clearly, an ecological theoretical framework resonates strongly with basic 
principles of women’s health research. Women’s health research provides a holistic 
approach that is for women, and in addition includes women in the intervention process. 
From this ecological viewpoint, women’s health issues are not separated from the social, 
political and economic forces in society that impact health and health decisions. 
Sociocultural and socioeconomic influences  
American women represent multiple cultures that are alternatively defined by 
race, ethnicity, gender, age, religion, occupational status, SES and family background. 
How women interact in society is influenced by their diverse backgrounds. As 
Bronfenbrenner (1979) suggested individuals are influenced by the cultural expectations, 
perceptions and beliefs of the community and culture of which they are a part. 
Bronfenbrenner’s ecological model provides a framework that enables researchers to 
assess the impact of culture and provides a broader picture of women’s health and 
developmental transitions (i.e.; menarche, puberty, and menopause). The model 
incorporates personal experiences of women as a source of knowledge and insight about 
the connection between the individual and the environment. This acknowledgement 
enables women’s health researchers’ ways in which to analyze the differences within and 
between cultural groups as well as how the groups are constructed and sustained in 
various environmental contexts. In addition economically disadvantaged women’s 
perceptions and experiences of menopause have largely been ignored in the assessment of 
menopause, especially in biomedical research. As mentioned previously, economically 
disadvantaged individuals often have poorer health outcomes 
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According to Bronfenbrenner (1979) “an ecological transition occurs whenever a 
person’s position in the ecological environment is altered as a result of a change in role, 
setting or both” (p.26). For women, the transition into midlife or their post reproductive 
lives is signaled by the cessation of menses and reproductive senescence. This 
menopausal transition, occurring most commonly during midlife can be considered an 
ecological transition. Bronfenbrenner (1979) notes that ecological transition is often 
alteration of both biological and environmental factors thus representing the process of 
“mutual accommodation” (p. 27), the basic tenet of ecology of human development. 
Transitions occur throughout the life span and are often wonderful times to address health 
behaviors in the context of health promotion and age related disease prevention. 
Developmental transitions (i.e.: puberty, adolescence, menopause, retirement) represent 
opportunities, which encourage the transformation of the physical, mental and social self 
(Schulenberg et al., 1997). Ecological transitions typically involve changes at the 
individual, microsystem and mesosystem levels. The links between microsystems prior to 
transition (i.e., focus on the care of others such as the growing family, reproductive health 
care needs) and then post transition microsystems (i.e., empty nest, focus on self and 
health behaviors in the post reproductive phase, aging parents, etc.) can be considered 
mesosystems as well, suggesting the importance of contextual influences on successful 
adaptation during transitions (Bronfenbrenner, 1979). 
For most women, natural menopause occurs at a time in life when role transitions 
are also occurring (growing children, empty nest, financial hardships related to putting 
children through college, aging parents, etc.), but not all women are going through these 
processes (i.e. surgical menopause, premature menopause, late childbearing). The 
ecological framework helps to facilitate the understanding of the individual’s experience 
of this transition. The onset of menopause with or without significant symptoms may lead 
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some women to interact with the health care system if available and accessible to them, 
therefore this time of transition can provide an open opportunity for health care providers 
to educate women on ways to enhance well being and promote health as they age and 
work through the menopausal transition. 
The health and well being of menopausal women should not be viewed as a single 
dimension such as a state of estrogen deficiency. Health and well being of women can be 
enhanced by an ecological perspective that is able to assess the multiple dimensionalities 
of the woman, her family, extended family, community and her environmental 
interactions with respect to adoption of personal health behaviors related to symptoms 
experience during the transition of menopause. Through ecologically oriented research 
aging issues are also viewed as public health issues that can lead to the identification of 
the value of health promotion and disease prevention at a national level. An enhanced 
focus on health promotion is an integral part of preserving independence and reducing 




According to the World Health Organization (WHO) and the International 
Menopause Society (IMS) the term perimenopause is the appropriate term to describe the 
period immediately prior to menopause and including the first year following menopause 
(Council of Affiliated Menopause Societies (CAMS), 2004). 
Menopause 
Menopause (natural menopause occurring without pathology or medical 
intervention) is defined as the permanent cessation of menstruation resulting from the 
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loss of ovarian follicular activity. Because there is no clear biological marker, the 
diagnosis of natural menopause is made retrospectively after 12 consecutive months of 
amenorrhea, for which there is no other obvious pathological or physiological cause 
(CAMS, 2004). This retrospective nature of diagnosing menopause and the overlapping 
of period of what is termed perimenopause provides insight into why the terms can be 
used interchangeably.  Hereto forward the terms perimenopause and menopause may be 
used interchangeable based on the source information.  
Menopausal Aged Women 
The mean age of menopause in the United States and most of the industrialized 
world is approximately 51.3 years with a range from 44-55 years of age (Speroff& Fritz, 
2005; Zacur, Appling, Freedman & Montgomery-Rice, 2002). Women, particularly those 
who live in underdeveloped countries may experience menopause at a younger age, such 
as the early or mid fourth decade of life (Beyene, 1989; Zacur, Appling, Freedman & 
Montgomery-Rice, 2002). Perimenopausal symptoms can appear in women 
approximately 6-10 years before the onset of menopause. Therefore the term menopausal 
aged women will reflect women between the ages of 40-55 years of age (Love, 2003; 
Zacur, Appling, Freedman & Montgomery-Rice, 2002). 
Hormone Therapy  
For the purposes of this study, HT is defined as the use of the sex hormones, 
estrogen and/or progesterone during menopause. There are several acronyms in 
menopause and hormone replacement literature which relate to HT, such as estrogen 
therapy (ET), combined estrogen-progesterone therapy (EPT), to name a few. Within this 
text the term HT shall encompass all types HT whether combined 
estrogen/progestin/testosterone or estrogen alone. 
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Vasomotor Symptoms 
Vasomotor symptoms describe a collection of menopausal phenomena including 
hot flashes or hot flushes and night sweats. A hot flash or hot flush is a sudden feeling of 
warmth and often a breakout of sweating usually confined to the chest, neck, face and 
head. There is an intense feeling of heat that often initiates in the chest area and spreads 
to the face head and neck. When hot flashes occur at night, they are often accompanied 
by night sweats which can disrupt sleep patterns (Freedman, 2001, 2002c, 2005; Speroff 
& Fritz, 2005), within in this text the terms vasomotor symptoms or hot flashes may be 
used interchangeably.  
Complementary and Alternative Medicine 
The National Center for Complementary and Alternative Medicine (NCCAM) 
defines Complementary and Alternative Medicine (CAM) as a “group of diverse medical 
and health care systems, practices, and products that are not presently considered to be 
part of conventional medicine (NCCAM, 2005) pg.1”. 
Complementary and Alternative Medicine are not synonymous; complementary 
medicine utilized along with conventional medicine, such as the term complementary 
suggests. Complementary simply means to balance or harmonize with (NCCAM, 2005). 
For example, utilizing meditation to relax and reduce vasomotor symptoms along with 
HT. 
Alternative medicine on the other hand is when modalities are used in place of or 
instead conventional medicine (NCCAM, 2005). An example of an alternative therapy 
may include the use of homeopathic medicine or meditation to reduce vasomotor 
symptoms instead of medical treatment with hormones or other prescribed drugs. 
The NCCAM breaks down CAM into five categories; the first is alternative 
medicine, which may include modalities such as homeopathic medicine and naturopathic 
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medicine. The second is that of mind-body intervention which includes meditation, 
prayer, or therapies that use creative outlets such as art, music, or dance. Third are 
biologically based “natural” therapies such as herbs, foods, and vitamins. Fourth are 
manipulative and body-based methods such as chiropractics or and massage. And lastly, 
the fifth category is labeled energy therapies, which would include biofield therapies such 
as Reiki, and Therapeutic Touch or bioelectromagnetic based therapies using 
electromagnetic fields (NCCAM, 2005). 
Macrosystems 
Macrosystems consist of broad cultural and historical influences of which all the 
other systems are embedded within (Bronfenbrenner, 1979). Macrosystems are 
operationalized for this study as pivotal clinical trials influencing menopause symptom 
management modalities (i.e.: HERSI & II and WHI). Macrosystems also include the 
subsequent consensus statements aimed at guiding clinical practice that closely followed 
the publication of the WHI findings (see figure1& 2. also see appendix 1, section 4: what 
influenced your decision to stop taking HT). 
Exosystems/Mesosystems 
Mesosystems are those settings in which the individual interacts in more than one 
setting either alone or through linkage of a third party and/or by the “intersetting” of 
knowledge through written communications such as pamphlets and books. Mesosystems 
are actually interrelations among microsystems described in the next paragraph. This 
level also includes exosystems which include influential external contexts such as a 
woman’s work, school or church settings or that of her family and close acquaintances. 
The mesosystem and exosystems is operationalized in this study as the influences of 
health care provider, pharmacist, husband, life partner, coworkers of friends a well as 
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popular media such as written word, television and Internet (see figure 1&2, also see 
appendix 1, section 4: what influenced your decision to stop taking HT). 
Microsystems 
Microsystems consist of an individual’s genetic make up as well as a place or 
setting where individual is engaged in close face-to-face interactions with others, such as 
the home, extended family, work or school settings. Microsystems are operationalized in 
the questionnaire as contextual factors that may influence menopause experiences as 
follows: 1) ethnicity, 2) income 3) education 4) age, 5) length of time post menopause, 6) 
body mass index (height and weight), 7) type of menopause, 8) presence of hot flashes 
prior to HT use 9) severity of current hot flashes, 10) length of HT use, 11) smoking, and 
12) alcohol consumption as well as 13) geographical location (see figure 1&2; also see 
appendix 1, section 2: hormone demographics &section 3: menopause history).  
Figure 2: Dissertation Model 
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Adequate studies exist that have assessed diverse groups of menopausal aged 
women with respect to the actual use or nonuse of HT, including use in low income 
women (Appling, Allen & Bellatoni, 1999; Appling, et al., 2000; Bartman & Moy, 1998), 
African American women (Holmes-Rovner, et al., 1996) and Hispanic women 
(Longworth, 2003).Yet there is little information available on women who are 
withdrawing from HT.  The recent historical events have led to an increase in the number 
of women who are now choosing to discontinue or not begin hormone therapy (HT) at all 
(Hersh, Setanick & Stafford, 2004). There is a dearth of information about the 
menopausal experiences of women who have never used or have discontinued HT. Thus 
there is a great need for research to investigate the experiences of women who are 
discontinuing therapy.  It is also important to understand the contextual factors associated 
with those experiences in order to identify women who may experience difficulties with 
withdrawal from hormones. Many women have chosen to treat their symptoms with 
alternatives therefore it is imperative that we start to explore the use of alternative 
medical treatments and CAM therapies as well as women’s perceptions of effectiveness 
so that further studies can be designed to assess risks, benefits, safety and efficacy of 
these therapies.  
The ecological model is a complex and abstract theoretical framework that 
elucidates the interconnectedness of the person and the environment. Although the theory 
lacks parsimony, the basic tenets of the theoretical framework are in a sense very 
intuitive within a nursing science perspective. Regardless of the abstract nature, 
acknowledgement of the interconnectedness between systems of the individual 
 26
(microsystems, mesosystems, exosystems and macrosystems) can play in integral role 
women’s health research.  
The ecological framework provides a useful guide to assess factors that may 
influence a woman’s experience of menopause and adoption of health behaviors to 
manage symptoms, if indeed symptoms occur. The ecological model described by 
Bronfenbrenner (1979) provides a theoretical framework that can be used to guide 
research with women regarding their experiences of menopause. The model is useful in 
providing a framework for a research design that can help to elucidate what the 
experience of menopause after discontinuation of HT will look like through this 
multifaceted lens. The model will help define the macro-environmental and societal 
factors (i.e.; culture, religion, spirituality, family, community, historical events, health 
care trends) that affect the care of menopausal aged women, especially those that are 
experiencing vasomotor symptoms. An ecological model also includes biological factors 
(health risks such as urogenital atrophy, cardiovascular disease, osteoporosis) associated 
with menopause that vary within a cultural context.  The findings of research driven by 
an ecological perspective will lead to identification of individual contextual factors 
associated with menopausal symptoms so that women at risk for return of symptoms can 
be appropriately counseled and assisted through the transition of with drawing from 
hormones. It will also lead to an understanding of the types of CAM that women accept, 
use and perceive as useful so that these modalities can be identified  and studied further 
to ensure safety and efficacy.  
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Chapter Two: Review of the Literature 
ETIOLOGY OF VASOMOTOR SYMPTOMS  
Research has shown that vasomotor symptoms in menopausal women are in part 
related to a decrease in endogenous estrogen levels as they occur when estrogen levels 
drop and are readily relieved by HT (Freedman, & Blacker, 2002; Kasuga, 2004; Weiss, 
2002).  Vasomotor symptoms are far more complex than previously thought and the 
underlying mechanisms behind them are poorly understood. Several theories have 
emerged over the years and understanding these mechanisms is extremely important in 
the development of alternative methods to relieve symptoms. These theories are included 
in this review because they provide an understanding of the etiologic factors that drives 
current research and uses of alternative treatments for vasomotor symptoms. It is 
important to note that while these theories provide some understanding of vasomotor 
symptoms with the onset of menopause, it is unknown if these same theories would apply 
to vasomotor symptoms occurring after the discontinuation of hormone therapy.  
Thermoregulation Dysfunction 
The predominant theory of vasomotor symptoms is that of a dysfunction in the 
central thermoregulatory center. Vasomotor symptoms occur as a way to dissipate heat 
when the core body temperature rises above a certain set point. The core body 
temperature rises, peripheral dilation occurs causing flushing followed by sweating and 
cooling of the body with sweat evaporation. Core body temperature (Tc) is regulated by 
the hypothalamus. In menopausal women, this dysfunction of the thermoregulatory center 
in essence is a narrowing of the temperature regulating zone in women susceptible to hot 
flashes. Thus even a small increase in temperature could trigger the heat loss mechanism 
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resulting in hot flashes (Freedman, 2001, 2002b, 2002c; Freedman & Krell, 1999). 
Freedman (1995; 2002a, 2002c, 2005) also found that the thermoregulation zone in 
menopausal women may be in fact narrowed on both sides, where even the low Tc 
threshold is increased resulting in an increased rate of shivering in women after a hot 
flash.  It has been postulated that the narrowing of the thermoregulation zone is caused by 
elevated levels of norepinephrine. 
Freedman and Subramanian (2005) explored the Tc variation, sweating thresholds, 
sweat rate controlling for serum estradiol and progesterone, and BMI in three groups of 
women. These groups consisted of 12 symptomatic menopausal women, 10 
asymptomatic menopausal women and 12 women with normal menstrual cycles. The 
researchers found that symptomatic women had a narrower thermoregulation zone than 
asymptomatic women or non-menopausal women. The results remained the same even 
when controlling for serum hormone levels and BMI. 
Neuroendocrine Pathways 
Norepinephrine 
Emerging research has shown that complex neuroendocrine pathways involving 
norepinephrine, estrogen, testosterone, serotonin and endorphins may also play a role in 
thermoregulation. Norepinephrine is increased just before and with hot flashes. 
Norepinephrine plays its role through Alpha-adrenergic receptors. Estrogens modulate 
the adrenergic receptors in many tissues including the hypothalamus (Casper & Yen, 
1985; Freedman & Woodward, 1992; Freedman, Woodward, & Sabharwal, 1990).  
Studies measuring norepinephrine and hot flash experience have been 
inconclusive with regard to the presence of brain norepinephrine during hot flashes 
because it is difficult to assess true brain levels (Freedman & Woodward, 1992; 
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Freedman, 2000). Freedman and Woodward therefore measured plasma 3-methoxy-4-
hydroxyphenylglycol (MHPG) which is the main metabolite of norepinephrine in the 
brain and its peripheral metabolite vanillylmandelic acid (VMA) as proxy measures for 
brain norepinephrine levels. The authors found that there were significantly higher levels 
of MHPG in the 13 symptomatic women compared to the 6 asymptomatic menopausal 
women indicating an increase in brain norepinephrine levels is associated with hot 
flashes. These findings are consistent with earlier studies with Clonidine, a α2-adrenergic 
agonist to reduce central noradrenergic activation and thus hot flushes (Clayton, Bell & 
Pollard, 1974; Laufer, Erlik, Meldrum, & Judd, 1982).  
Serotonin  
Serotonin (5-HT) levels have been shown to be decreased in natural or surgically 
menopausal women. When estrogen is given the values have been shown to return to 
normal (Gonzales & Carillo, 1993). Low serum estrogen levels have been associated with 
high concentrations of the 5-HT2A receptor subtype on platelets, thus it may play a key 
role in the occurrence of hot flushes. Basically, estrogen withdrawal decreases 5-HT in 
the blood stream which increases the 5-HT2A receptors in the hypothalamus which is 
involved in thermoregulation as has been noted previously. Increases in 5-HT2A receptors 
results in a change in the thermoregulation set point causing a need for heat dissipation as 
is seen in hot flashes. Blocking the 5-HT2A receptors could result in reducing hot flashes.  
Treatment with a selective serotonin reuptake inhibitor activates the 5-HT2C receptor 
which will in turn inhibit the 5-HT2A receptors (Berendsen, 2000).   
MACROSYSTEMS INFLUENCES 
The literature review that follows is constructed according to the ecological 
framework of this study. The macrosystems within an ecological model consist of broad 
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cultural and historical influences in which all the other systems of the ecological 
framework are embedded (Bronfenbrenner, 1979). This section describes those historical 
events that have led to recommendations to changes in HT prescribing and utilization. 
Pivotal Clinical Trials 
Findings from the Heart and Estrogen/progestin Replacement Study (HERS) were 
published in the Journal of the American Medical Association (JAMA) in August of 
1998. The trial was to provide clinical evidence to support epidemiologic data suggesting 
there were lower rates of coronary heart disease (CHD) in postmenopausal women who 
took estrogen than in women who did not (Derby, 2000; Grady, Rubin & Petitti, 1992; 
Hughes, 1990; Psaty, Heckbert & Atkins, 1994; Sidney, Petitti & Quesenberry, 1997; 
Stampfer & Colditz, 1991; Sullivan, et al., 1990). HERS was a randomized, blinded, 
placebo-controlled clinical trial designed as a secondary prevention trial for women with 
established coronary disease to determine if estrogen plus progestin therapy alters the risk 
for CHD events.  This study included a total of 2763 women with coronary disease with 
an average age of 67 years. The women were randomly assigned to receive either 0.625 
mg of conjugated equine estrogens (CEE) plus 2.5 mg of medroxyprogesterone acetate 
(MPA) or a placebo. The women in this first report of the HERS trial were followed for 
an average of 4 years. The primary outcome variables were the occurrence of nonfatal 
myocardial infarction (MI) or CHD death. No significant differences between groups 
were found for the primary outcomes of the trial. Despite the lack of differences between 
the groups with regard to the primary outcome variables, there was a statistically 
significant time trend, with more CHD events in the hormone group than in the placebo 
group in the first year followed by fewer events in the 4th and 5th years of the trial. Given 
the findings of no apparent cardiovascular benefits with regard to MI or CHD deaths in 
the treatment group versus placebo and the additional findings of an increase in CHD 
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events in the first year for the treatment group, the researcher group recommended that 
estrogen not be given for the purpose of secondary prevention of CHD. Interestingly, 
they also found that women who received the treatment did have a statistically lower low-
density lipoprotein (LDL) cholesterol level and a higher high-density lipoprotein (HDL) 
cholesterol level compared with the placebo group. Therefore it was recommended that 
women already on treatment could continue, given the trend towards a decrease in CHD 
events in years 4 and 5 (Hulley, et al., 1998).  
The Follow Up Heart and Estrogen/progestin Replacement Study II (HERS II) 
was designed to determine if the decrease in risk of nonfatal MI and CHD that was found 
in years 4 and5 of the HERS continued with the additional years of follow-up. HERS II 
followed up the HERS trial for an additional 2.7 years. HERS II was un-blinded and 93% 
of the original participants consented to continue with this follow up. HERS II was an 
open-label trial where hormone therapy was prescribed at participant’s personal 
physicians' discretion. The primary outcomes remained the same as nonfatal myocardial 
infarction and CHD death.  At the completion of the follow up the research group found 
that the lower rates of CHD events noted previously among women in the hormone group 
in the final years of HERS did not continue in the following years. Recommendations 
following this trial were again simply that postmenopausal hormone therapy should not 
be used to reduce risk for CHD events in women with preexisting CHD (Grady, et al., 
2002). 
The Women's Health Initiative (WHI) is a long-term national health study 
designed to provide information that will help in preventing heart disease, breast and 
colorectal cancer and osteoporosis in postmenopausal women. The WHI was sponsored 
by the National Heart, Lung, and Blood Institute (NHLBI) and is one of the largest 
clinical trials of women's health ever undertaken in the U.S. The WHI study has three 
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parts, which include the randomized clinical trial that will be discussed in the following 
text, an observational study and a community prevention study (www.WHI.org, 2005). 
Findings from the Women’s Health Initiative (WHI) clinical trial were published 
in JAMA in July 2002. The WHI was designed to assess the major health benefits and 
risks of conjugated equine estrogen (CEE), the most commonly used exogenous estrogen 
in the United States. Recruitment from several clinical sites occurred between 1993 and 
1998. This was a randomized controlled primary prevention trial designed to last 8 ½ 
years. The WHI participants were randomly assigned either to the treatment group, which 
received CEE 0.625 mg/d, plus MPA, 2.5 mg/d or placebo. Similar to the HERS trials, 
the primary outcome was non-fatal MI or CHD death and invasive breast cancer was the 
primary adverse outcome. Unlike other trials, a global index was set up prior to the onset 
of the study so that if the risks outweighed the benefits, the trial would be stopped.  The 
balance of risks and benefits included the 2 primary outcomes in addition to the 
occurrences of stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, 
hip fracture, and death due to other causes (Rossouw, et al, 2002). 
The WHI trial was stopped just after 5 years when the data and safety monitoring 
board recommended stopping the trial because the global index of risk versus benefit 
exceeded the previously set limit for invasive breast cancer adverse effect and the global 
index statistic supported risks exceeding benefits. The findings at this time revealed 
absolute risks per 10 000 person-years that were attributable to estrogen plus progestin 
were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast 
cancers. As for absolute risk reductions per 10 000 person-years there were 6 fewer 
colorectal cancers and 5 fewer hip fractures. The authors concluded that the findings from 
this trial did not support the initiation of or the continuation of CEE/MPA for primary 
prevention of chronic diseases (Rossouw, et al, 2002).  
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Consensus Statements 
The trials described previously have been hotly debated resulting in several 
organizations providing consensus statements to guide health care providers. The 
American College of Obstetrics and Gynecology (ACOG) states that it is important to 
understand that different forms of hormone therapy are associated with different risks. 
And those women without a history of cardiovascular disease (CVD) or breast cancer 
who are currently use hormone therapy, it is recommended that they use the lowest 
effective dose for the shortest possible duration. In addition, ACOG also recommends the 
use of selective serotonin re-update inhibitors (SSRI) for the relief of vasomotor 
symptoms. Finally, the recommendations state that hormone therapy should not be used 
solely for the purpose of osteoporosis prevention as there are other treatment modalities 
such as biphosphonates or selective estrogen receptor modulators (SERMS) that are also 
effective in treating and/or reducing this risk (American College of Obstetricians and 
Gynecologists, 2004) 
The American Heart Association (AHA) states that there is no research to support 
that hormone therapy is beneficial for primary prevention of CVD.  Thus hormone 
therapy should not be initiated for secondary prevention of CVD. Treatment or non-
treatment in women currently on HT should be individualized based on the patients’ 
history, preferences and proven noncoronary benefits and risks. In the event that a 
woman develops CVD or is to be immobilized, hormone therapy should be discontinued 
to reduce risk of VTE. (Burger & Teade, 2001; Mosca, et al., 2001). 
The American Society of Reproductive Medicine (ASRM) recommends that 
treatment of patients during the menopausal transition should be based primarily on 
symptom experience (American Society of Reproductive Medicine [ASRM], 2005).  
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The National Institute of Health (NIH) consensus statement on the “Management 
of Menopause-related Symptoms” in March of 2005 recommends the hormone therapy is 
only indicated for the treatment of vasomotor symptoms and thus should be used only for 
that purpose at the lowest possible dose for the shortest period of time (The National 
Institute of Health, 2005).  
The FDA also recommends that estrogens should only be prescribed for the 
treatment of menopausal and urogenital symptoms at the lowest possible dose for the 
shortest time possible (U.S. Food and Drug Administration, 2004).  
The North American Menopause Society (NAMS) provides the most 
comprehensive position statement to guide clinical practice. NAMS recommends that for 
women who are experiencing only mild vasomotor symptoms use of nonprescription 
complementary alternative methods should be offered despite the lack of evidence to 
support the effectiveness of these methods. For women with severe symptoms, HT 
remains is recommended (North American Menopause Society, 2004 a,b,c,d). 
MESOSYSTEMS/EXOSYSTEMS INFLUENCING VASOMOTOR SYMPTOM EXPERIENCES 
Mesosystems are interrelations between microsystems of others. These 
mesosystems can include social networks, communities and peer groups or even health 
care clinics within which the dyad interacts.  Exosystems represent influential contexts 
outside of the individual’s microsystems but within the microsystems of an individuals 
parents', children’s or a spouse’s school, work, social or community settings. For the 
purpose of this study, exosystems and mesosystems described here are that of the health 
care providers’ attitudes and prescribing habits as well as the attitudes of women in 
response to the macrosystems historical influences (i.e.: pivotal trials and resulting 
consensus statements). Mesosystems such as family members, alternative health care 
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providers, and lay literature have also led to interest in and use of alternative treatments 
for vasomotor symptoms as caution increases over HT use. 
Trends in attitudes and vasomotor symptom management 
In the wake of WHI, studies now emerging have found that clinical practice has 
changed in that there has been a decrease in new prescriptions for hormones as well as a 
noted decrease in the dosage if of current prescriptions for hormone therapy (Haas, 
Kaplan, Gerstenberger, & Kerlikowske, 2004; Hersh, et al., 2004; MacLennan, Taylor, & 
Wilson, 2004). In addition, studies that have also found a definite change in patients and 
health care provider attitudes towards hormone therapy in the wake of WHI.  These 
studies have shown more caution in the weighing of benefits and risk with a trend 
towards decreasing the dosage of HT if therapy would continue as well as discontinuance 
of therapy (Blümel, et al., 2004; Bosworth, et al., 2005; Ekström, 2005; Haas, et al., 
2004; Leung, Ling, & Tang, 2005; MacLennan, et al., 2004; Rolnick, Kopher, DeFor, & 
Kelley, 2005). Despite the knowledge of the growing trend to discontinue hormone 
therapy, information is lacking on how this trend will affect women’s menopausal 
experiences.  
Adoption of Complementary and Alternative Medicine trends 
With more and more women discontinuing HT during this time, little is known 
about the changing attitudes and adoption of complementary alternative medicine (CAM) 
therapies especially in women who have discontinued HT. Prior to WHI several studies 
have explored the use of CAM.  
Kaufert and colleagues (1998) found that nearly 80% of the menopausal women 
surveyed at health conference utilized CAM (herbs, yoga, TCM) to treat menopausal 
symptoms. Newton and colleagues (2002) conducted a telephone survey of over 800 
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hundred women aged 44-65 and found that 75% of the women use CAM and 22% 
utilized CAM specifically for menopausal symptoms. The women surveyed in these 
studies were predominantly White and well educated. 
Factor-Litvak and colleagues (2001) conducted a pilot survey via phone interview 
of a more diverse group of 300 women (100 White, 100 African American, and 100 
Hispanic) in New York City. The authors found that over 50% of the women used some 
type of CAM therapy and 40% had visited a CAM provider without any significant racial 
or ethnic differences. 
Bair and colleagues (2002, 2005) examined the use of CAM among midlife 
women who participated in the Study of Women’s Health Across Nations (SWAN). The 
SWAN, is a 10-year cohort study of over 3300 women from varied ethnicities including 
African American, Hispanic, Japanese, Chinese and Caucasian. The authors found that 
nearly half of the total participants utilized some type of CAM therapy. Consistent with 
other surveys, those who utilized CAM were more likely to be older, married, higher 
SES, and reported lower health status than nonusers. The authors also found no racial and 
ethnic differences.   
Kronenburg and colleagues’ (2006) study represents the most recent data related 
to the women’s adoption of 11 domains of CAM (excluding only religion and 
spirituality) use across racial/ethnic groups.  The authors found that CAM use was high 
across all ethnic and racial groups. The highest overall use of CAM occurred in non-
Hispanic White and Chinese American women. Women in this group tended to use a 
wider variety of CAM modalities and visited a CAM provider more than other groups. 
The authors also found that Hispanic women tended to use herbs and Chinese American 
women used acupuncture more often than other groups. Although not specific to 
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menopause this exciting study illustrates the increased use of CAM by women in all 
ethnic and racial groups.  
The survey research presented here has illustrated that essentially all cultural 
groups of women adopt CAM, except that there is less utilization in women of lower 
socioeconomic status.  Consistently, the most significant predictive demographic factors 
of socioeconomic status were that of income and educational level.  The cost of herbal 
supplements and CAM therapies can be significant and in most cases is not covered by 
prescription health plans or state subsidized health care plans if indeed they have any 
health care insurance coverage.  Given the historical changes that have occurred, it is 
important to see how attitudes and adoption of CAM have changed in the post WHI 
period with regard to adoption of CAM modalities specifically for menopause symptoms.  
A review of the lay menopause literature was performed to assist in developing 
the list of CAM therapies for the questionnaire used in this study. The review found, 
interestingly enough, that out of the 700 texts, only two were intended for Hispanic 
women, and only one of the texts was available in the Spanish language (Vera, 2003). 
Only two books were located that discussed experiences and recommendations of 
menopause for African American women (Porter & Gaston, 2001; Scott-Brown, 2003). 
This clearly reflects a lack of culturally sensitive informative texts that may leave many 
women without knowledge of available measures to enhance health and well-being and 
or treat menopausal/vasomotor symptoms during menopause. 
MICROSYSTEMS INFLUENCING VASOMOTOR EXPERIENCES 
Ethnicity and Race 
The predominant biomedical perspective makes the assumption that menopause is 
a universal experience. Yet, although there is a biologic universality, it is becoming 
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increasingly clear that a woman’s experience of menopause can be quite varied within the 
context of culture, ethnicity and community. Lock and Kaufert (2001) challenge the 
notion that the experience of menopause is universal and suggests that not all women are 
at equal risk for morbidity measures associated with menopause and women should be 
looked at in what she terms “local biologies”, which include varied cultural, social and 
psychological experiences. 
For example, Beyene (1989) found that Mayan women in a Yucatan village 
experienced menopause a few years earlier than Western women. In addition, these 
women did not have a concept of menopause as a disease state as Western women do. 
Beyene contends that this perception is possibly a factor in why these Mayan women do 
not experience symptoms related to menopause.  
Lock and Kaufert (2001) note that Japanese women report far less symptoms than 
women from the US or Canada. In addition, these women did not appear to be equally at 
risk for the commonly expected morbidity of osteoporosis, heart disease or breast cancer. 
Beyene (1989) also found similar evidence with the Mayan women from the Yucatan as 
they too, did not appear affected by osteoporosis despite the early onset of menopause 
and lack of HT use.  
Avis and colleagues (2001) looked at the menopause experience across five 
racial/ethnic groups, African American, Caucasian, Chinese, Hispanic and Japanese. 
After controlling for age, education, health and economic strain, they found that 
Caucasian women experienced more somatic symptoms. African American women 
reported more vasomotor symptoms.  And finally, consistent with other studies they 
found that the group of Asian women reported fewest symptoms compared to all groups. 
Langenberg, Kjerulff and Stolley (1997) also found that Black women were more likely 
to experience hot flashes compared to White women. Miller and colleagues (2006) found 
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that although Black women had a higher risk for hot flashes it was related to other 
concurrent risk factors such as being a current smoker, lower estrogen levels and a, 
higher BMI than Caucasian women in their study. 
Gold, et al (2006) in their study of women’s health across the nation (SWAN) has 
followed large diverse group of menopausal women (n=16,065) from 1997 on. Women 
included in this study were White (n=1543), African American (n=930), Hispanic 
(n=284), Chinese (n=250) and Japanese women 9n281) from 7 different sites throughout 
the US. Gold and colleagues found conversely found that African American women in 
this study experienced less vasomotor symptoms when compared to white women 
(p=<.01).   
In contrast, Schwingl, Hulka, Sioban and Harlow (1994) did not find differences 
between Black and White women. Schwingl they found that socioeconomic status was a 
significant predictor of higher hot flash occurrences, not race. 
Family genetics or familial tendencies have also been suggested as predictive 
factors for menopausal transition experiences. Starpoli (1998) found that women whose 
mothers had experienced hot flashes also experienced them as well.  
The studies reviewed here have suggested that ethnic and cultural differences may 
affect vasomotor symptom experience in women, although the results have are 
conflicting. This is not surprising when viewing menopause through an ecological 
framework given the multidimensional makeup of each individual woman. 
Socioeconomic Status 
Socioeconomic status has been shown to be related to vasomotor symptom 
experience in women. Socioeconomic status can be defined by proxy measures of income 
and education.  Numerous studies have shown that lower educational status is associated 
with higher incidence of vasomotor symptoms (Chiechi, Fereri, Bianco, Berardesca & 
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Loizzi, 1997; Gold, et al., 2000; Li, et al, 2003; Neri, Demyttenaere & Fracchineeti, 
1997; Schnatz, Banever, Greene, & Sullivan, 2005). Consistent with low educational 
status, lower income or poor employment is also associated with an increase in 
vasomotor symptom reporting symptoms (Chiechi, et al., 1997; Gold, et al., 2000: Li, et 
al., 2003; Neri, et al., 1997).  
Body weight 
Body weight has been found in some studies to increase vasomotor symptoms 
(Campagnoli, et al, 1981; Wilbur et, al 1998).  Li and colleagues (2003) found that 
weight gain in menopausal women, among others factors were major risks for vasomotor 
complaints.  
Using BMI as measurement level, later studies have shown that a higher BMI was 
associated with a higher incidence of hot flashes (Chiechi, et al, 1997; Gold, et al, 2000; 
Gold et al, 2006; Langenburg, 1997; Starpoli, 1998) Using Odds Ratios (OR), several 
studies found higher BMI was associated with increased prevalence of hot flashes. 
Wilbur et al (1998) found an adjusted OR of 1.09. Whiteman (2003) reported that a BMI 
of over 30 kg/m2 was associated with an increased risk for hot flashes compared with 
those with a BMI less than 24.9 kg/m2 (adjusted OR = 2.1, 95% CI 1.5, 3.0).    
Starpoli, et al (1998) found no association between BMI and hot flashes. 
Conversely, two studies found that women with lower BMI were more likely to have hot 
flashes (Guthrie, et al, 1996; Schwingl, et al, 1994), although in one of these studies this 
factor was mediated by positive smoking status (Schwingl, 1994).  
Smoking 
Several studies have shown that hot flashes are increased in smokers (Avis, et al, 
1997, Gold, et al, 2000; Kuh, Wadsworth & Hardy R., 1997; Starpoli, 1998; Whiteman, 
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2003). Avis calculated OR of increased frequency of hot flashes of 1.44 and 1.57 for 
bothersome nature of hot flashes.  Kuh, et al. (1997) reported an OR of 1.6 for ever 
smokers and the prevalence of hot flashes. Starpoli (1998) reported an OR of 1.1 for 
current smokers with pack years < 40 and OR of 2.5 for pack years >40.  Gold and 
colleagues (2000) found OR of 1.68 in current smokers who smoked over 20 cigarettes 
per day. Whitman and associates (2003) found that women who were current smokers 
were at an increased risk for hot flashes had an adjusted odds ratio OR of 1.9 and the risk 
of hot flashes increased as the amount of smoking increased.  
One study failed to show an association with smoking and the experience of hot 
flashes (Gannon, Hansel & Goodwin. 1987) The authors reported from this small study 
with 10 women that stress and anxiety were related to hot flashes but not alcohol or 
smoking. 
Type of Menopause 
Langenburg (1997) found that HT was most commonly recommended for women 
who have had a hysterectomy/oophorectomy for noncancerous conditions. In addition, 
there is agreement that women who experience surgical menopause encounter more 
vasomotor symptoms than women who have not. Studies have shown that number of 
women in this group experiencing vasomotor symptoms reaches nearly 90% 
(Chakravarti, et al., 1977; Feldman, Voda, & Gronseth, 1985).  
Kritz-Silverstein (2003) in a study with 1121 women aged 50-89 the authors 
found that the duration of estrogen use was longer for women who had a hysterectomy 
than women who experience natural menopause (p <0.001). Interesting to note, that 
among current estrogen users, the authors reported that positive feelings were 
significantly higher in women who had a hysterectomy, with or without bilateral 
oophorectomy (p < 0.01) than in women with natural menopause. In the post WHI period 
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Bosworth and colleagues (2006) recently published their findings from a study looking at 
factors related to discontinuation and initiation of HT. The researchers found that women 
who underwent surgical menopause were less likely to discontinue HT as compared to 
those who experienced natural menopause.  
A recent study also suggests that HT does not entirely eliminate vasomotor 
symptoms in pre-menopausal women who have undergone a total hysterectomy and 
bilaterally oophorectomy. This could lead to continued use and unsuccessfully 
discontinuing HT as well (Madalinska, et al., 2006). All of these studies strongly suggest 
that surgical menopause increases the risk for vasomotor symptoms. 
Age/ Menopause status (years post menopause) 
Gold and colleagues (2000) did not find age to be associated with vasomotor 
experiences. Two studies (Gold, et al, 2006; Li et al, 2003) found that the older a woman 
was the more likely they would have hot flashes, but these studies also included 
perimenopausal women, therefore it is not surprising that the older the woman the more 
likely hot flashes would occur as they near menopause. Gold et al, (2006) also found that 
the more years post menopause, the less likely they would experience hot flashes.  
Symptom experience prior to onset of hormone therapy 
Three studies have reported vasomotor experiences of women who are 
discontinuing HT, one before the release of WHI study findings (Hammar, et al, 1999) 
and two after (Grady, et al., 2003; Ockene, et al., 2005). These studies suggest occurrence 
of vasomotor symptoms prior to HT is a significant predictor of the experience of the 
occurrence of vasomotor symptoms after discontinuation of HT. These studies were 
discussed in great detail in chapter 1. 
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Geographical Distribution 
As has been elucidated earlier the most predominant theory of vasomotor 
symptoms is that of a dysfunction in the central thermoregulatory center. Vasomotor 
symptoms occur as a way to dissipate heat when the core body temperature rises above a 
certain set point. Even small increases in temperature may trigger the heat loss 
mechanism resulting in hot flashes (Freedman, 1998, 2001, 2002a, 2002b, 2002c, 2005, 
Freedman & Blacker, 2002, Freedman & Dinsay, 2000, Freedman & Krell, 1999, 
Freedman, Norton, Woodward, & Cornélissen, 1995). Given this theoretical framework, 
it is possible that geographic location may play a part in the experience of hot flashes in 
women living in warmer climates or during warmer seasons. Sievert and Flanagan (2005) 
analyzed hot flash frequencies from 54 studies.  They found that menopausal women in 
warmer temperatures actually had fewer hot flashes than women in colder climates. The 
authors suggest that perhaps women in these warmer climates be accustomed to the 
warmer climate and are less sensitive to increases in temperature. 
Hormone therapy discontinuation type 
Two of the discontinuation studies discussed earlier have suggested that how 
discontinuation occurs does not necessarily reduce the occurrence of vasomotor 
symptoms after discontinuation of HT (Grady, et al, 2003; Ockene, et al, 2005). Only one 
small prospective study (N=91), was found that was specifically designed to look at 
discontinuation method. The researchers recruited women from May 2001 to June 2003 
that had been on HT for 3 years or more and desired to discontinue HT. The women 
opting to discontinue HT were randomized to one of two groups, either tapering 
discontinuation or abrupt cessation of HT (Haimov-Kochman, et al., 2006). The authors 
reported that tapering of HT did not reduce the return of HT, but instead only delayed the 
return.  The authors did feel that although the outcomes were similar the tapering of HT 
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may help to decrease the estrogen dose to the lowest effective dose as is the current 
accepted recommendation. These studies were discussed in depth in chapter 1. 
In summary, these studies provide evidence that microsystems such as 
ethnicity/race, socioeconomic status, body weight, smoking, type of menopause, age, 
symptom experiences at menopause onset, geographical and how HT is discontinued may 
be associated with the varied vasomotor symptom experiences in menopausal women. 
The studies results in general are conflicting with the strongest evidence related to type of 
menopause and the way in which HT is discontinued. Women with surgical menopause 
consistently have been shown to have more vasomotor symptoms than women who have 
progressed through natural menopause. The studies presented have also clearly shown 
that how HT is discontinued did not seem to have an impact on the return of vasomotor 
symptoms. These conflicting findings are not entirely surprising especially when viewing 
menopause through the lens of an ecological framework in which many factors affect 
women’s experience of menopause.   
MEDICAL TREATMENT FOR RELIEF OF VASOMTOR SYMPTOMS 
Hormone Therapy (HT) 
Estrogen 
HT is has long been considered as one of the most efficacious therapies for the 
treatment of vasomotor symptoms. Given its long history a Cochrane Database summary 
was published in 2004. The report found that the effects of estrogen for relief of hot 
flashes were sustained in trials of three months to three years duration with very few 
reports of serious adverse events or intolerable side effects. In addition the report states 
that the effectiveness and short term safety of oral HT for the alleviation of hot flushes 
and night sweats has been well established in clinical trials performed in symptomatic 
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perimenopausal and menopausal women. In addition, the report states that the longer 
term safety issues were reported in the findings of WHI study. The report did not attempt 
to differentiate between oral HT products, combinations, doses or regimens. According to 
the Cochrane Review there are no implications for further research with regard to safety 
and efficacy within the context of relieving vasomotor symptoms. Future research was 
suggested with regard to dosing to see if lower doses are similar in efficacy than current 
doses (Maclennan, Broadbent, Lester, S., & Moore, 2004).  
Progesterone 
Few recent clinical trials were found on the use of progesterone to relieve 
symptoms. Two older trials were found that studied the use of medroxyprogesterone 
acetate (MPA) (Morrison, et al., 1980; Schiff, Tulchinisky, Cramer, & Ryan1980). One 
trial utilized intramuscular MPA dosing and did not find any statistically significant 
improvement of symptoms (Morrison, et al., 1980). The second trial was a double blind 
crossover study of 27 women receiving oral MPA or placebo (Schiff, et al., 1980). A 
double-blind crossover study was designed to compare the effects of placebo and MPA 
on vasomotor symptoms 27 postmenopausal women. Both the treatment group and the 
placebo group had a decrease in symptoms after four weeks of use, 34% versus 73.0% 
respectively. But, when the treatment group crossed over to the placebo group, they 
began to have symptoms. This research suggests that MPA alone can help to relieve 
vasomotor symptoms. Recently use of MPA has become under fire as it was the 
progesterone studied with estrogen in the WHI trial and it has been suggested it that it 
may have a potentiating affect on breast cancer risk. 
Recently with the increase in use of botanicals, natural progesterone creams have 
been marketed to women purporting to improve vasomotor symptoms as well as 
alleviating a variety of other menopausal symptoms. In a double blinded, placebo 
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controlled trial, designed to assess the effectiveness of a progesterone cream on 
vasomotor symptoms Leonetti and colleagues (1999) randomly assigned 102 healthy 
menopausal aged women to one of two groups,  a transdermal progesterone cream or 
placebo group. The researchers noted that 83% of the women in the treatment group 
noted subjective improvement in vasomotor symptoms compared to only 19% of the 
placebo group suggesting that progesterone cream may be effective in reducing 
vasomotor symptoms. 
A second trial was also undertaken to determine the effectiveness of transdermal 
progesterone cream on vasomotor symptoms (Wren, Champion, Willetts, Manga, & 
Eden). Wren and colleagues (2003) performed a double-blind, randomized, placebo-
controlled trial comparing the effect of a transdermal cream containing a progesterone 
(32 mg daily) with a placebo cream. The researchers randomly assigned eighty 
postmenopausal to one of two groups, one would receive the progesterone cream and the 
other group would receive the placebo. The Greene Climacteric Scale and the Menopause 
Quality of Life Questionnaire were used to measure symptom relief. The authors did not 
find any significant differences between groups with regard to vasomotor symptom 
reporting.  
Androgens 
No studies were found specifically designed to assess the effectiveness of using 
testosterone alone for the relief of vasomotor symptoms. All studies used combined 
estrogen/testosterone interventions. 
Studies with testosterone often did not have vasomotor symptoms as the primary 
outcome, but instead the primary outcomes were primarily based on libido or sex drive 
(Lobo, Rosen, Yang, Block & van der Hoop 2003; Shifren, et al., 2000). In addition these 
studies were in essence confounded by the fact that testosterone was used in combination 
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with estrogen. Estrogen is known to relieve vasomotor symptoms. Adverse events such as 
lipid change, acne and hirsutism tend to be higher with the use of testosterone versus 
estrogen alone (Hickok, Toomey, & Speroff, 1993). Given the limited research available 
and the side effect profile, testosterone by itself may not be the best choice for reduction 
of symptoms.  
The use of dehydroepiandrosterone (DHEA) as a dietary supplement to reduce the 
symptoms of aging and improve well-being has increased despite the lack of evidence to 
support the safety and efficacy of its use. DHEA, an androgenic steroid hormone, has 
been shown to have an age-related decline. Perimenopausal women have only 
approximately 50% of peak DHEA levels. DHEA has neurosteroidal properties, and by 
exerting anti-gamma aminobutyric acid (GABA) action it may act like an antidepressant 
(Arlt, 2004). Two studies were found that looked at the use of dehydroepiandrosterone 
(DHEA) supplementation to relieve the symptoms of menopause In a randomized, 
double-blind placebo-controlled trial with 60 perimenopausal women, Barnhart and 
colleagues (1999) found that supplementation with DHEA did not alleviate or improve 
menopausal symptoms. In addition, may have some adverse effects on endocrine and 
lipid profiles.  
Stomati and group (1999) investigated the neuroendocrine and behavioral effects 
of three months of DHEAS supplementation in 22 postmenopausal women. The women 
were further broken down into three groups, the first group was treated with oral DHEAS 
(n = 8) the second treated with the same dose of oral DHEAS and transdermal estradiol 
(n = 8) (DHEAS)   and the third with transdermal estradiol alone (n = 6). In the groups 
treated with DHEAS, mean basal serum DHEA, DHEAS, androstenedione, and 
testosterone levels significantly increased after treatment, while no changes were shown 
in the group receiving estradiol alone. Vasomotor symptoms showed improvement in all 
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groups as measured by the Kupperman index. This study, although lacks significant 
statistical power provides some support for therapeutic efficacy of the DHEAS on 
menopausal symptoms. 
Given the conflicting results of these studies and the low power of the Stomati 
(1999) study, support is lacking with regard to effectiveness of DHEA to treat symptoms. 
Indeed, there may be adverse effects on lipid and endocrine parameters (Barnhart, 1999). 
Antidepressants 
As reported earlier, it has been postulated that hot flashes occur as a result of an 
alteration in the thermoregulatory set point in the hypothalamus following estrogen 
decreases. The exact mechanism of action by which venlafaxine or other antidepressants 
may ameliorate hot flashes has not been established; however, both norepinephrine and 
serotonin are thought to be involved in central thermoregulation. It is possible that 
antidepressant effects on these receptors may help reestablish the thermoregulatory set-
point.  
Clinical research studies have examined at the use of variety of antidepressant 
medications such as selective serotonin reuptake inhibitors (SSRI) such as paroxetine 
(Paxil®). Stearns, Beebe, Iyengar and Dube (2003) studied paroxetine in a double-blind, 
placebo-controlled trial. The researchers’ randomly assigned 165 menopausal women, 
who were experiencing at least 2 to 3 daily hot flashes and had discontinued HT for at 
least 6 weeks to one of three groups. The three groups consisted of a placebo arm, and 
two intervention arms with different paroxetine doses 12.5 mg/d or 25.0 mg/d. The study 
participants were followed for six weeks, with the main outcome measure of a mean 
change from baseline to week 6 in the daily hot flash composite score The hot flashes 
composite score was determined by the severity of the hot flash (mild = 1, moderate = 2, 
severe = 3, very severe = 4) multiplied by the daily number of hot flashes experienced at 
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that severity level. The authors found an equal improvement in the composite score for 
both the treatment groups. This study provides support for use of paroxetine to relieve 
symptoms although the dosing it is inconclusive because both groups had an equal 
improvement.  
Venlafaxine (Effexor®) is a selective norepinephrine reuptake inhibitor (SNRI) 
that has a slightly different mechanism of action from an SSRI. Evans, et al, (2005) 
conducted a 5-month study to assess the safety and efficacy of venlafaxine for the 
treatment of hot flushes in menopausal women. Sixty women (mean age 47.6 years) were 
randomly assigned to one of 3 treatment groups the placebo control group, venlafaxine 
37.5mg/day group or venlafaxine 75mg/day group. Due to high withdrawals from the 
venlafaxine 75mg/day group voluntarily withdrew; the intervention groups were 
collapsed into one single group receiving 37.5mg/day for an additional 4 months. 
Compared to the baseline assessment week, after the third week, hot flushes increased in 
the control group by 11%, and decreased in the venlafaxine treatment group.  
Grady-Weliky et al (2001) published a case report of 52-year-old women with a 
history of major depressive disorder, hysterectomy and a bilateral salpingo-
oopherectomy. The patient was placed on venlafaxine XR at 75 mg/day and complained 
of a return of hot flashes 2 weeks after starting venlafaxine. After 7 weeks on venlafaxine 
XR at 75 mg/day she noted a reduction in frequency and severity of hot flashes. The 
venlafaxine XR dose was titrated up to 150 mg/day and the patient noted increased 
frequency of hot flashes. The frequency and severity of her hot flashes were subsequently 
reduced after staying on the venlafaxine at 150 mg/day for an unspecified amount of 
time. The case report provides another viewpoint with regard safety and control of 
symptoms.  
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In summary, utilizing paroxetine or venlafaxine for hot flashes relief is an off 
label use of both drugs. With either the SSRI or SNRI although there is some suggestion 
they may improve symptoms, there is limited high level research to support their 
effectiveness in the relief of vasomotor symptoms.  
Other Medical Therapies 
Clonidine 
As described earlier norepinephrine has been indicated as part of the etiologic 
factors for hot flashes. The earliest study located was by Lindsay and Hart (1978). This 
was a double-blind crossover trial of Clonidine which failed to show any affect of the 
treatment on vasomotor symptoms. In a later study, Nagamani, and colleagues (1986) did 
find a significant effect with Clonidine in lowering symptoms in a randomized 
prospective double-blind study intended to evaluate the efficacy of transdermal Clonidine 
for the treatment of menopausal hot flashes. The authors found that a highly significant 
reduction in symptoms in patients receiving the Clonidine in that 80% reported fewer hot 
flashes; 73% a decrease in severity; and 67% a decrease in duration. Only 36% of the 
placebo group reported a reduction in hot flashes, 29% a decrease in severity; and 21%, 
shorter duration. Clonidine did not have a significant effect on lowering of blood pressure 
or pulse in this study.   
Gabapentin 
Given the neuroendocrine pathways etiologic factors the use the anticonvulsant 
gabapentin was looked at for the relief of hot flashes. Albertazzi and colleagues (2003) 
reported on an open case series of 11 postmenopausal women who agreed to take 
gabapentin on hot flushes for relief of vasomotor symptoms. The participants kept a daily 
diary of the frequency and severity of their vasomotor symptoms pre and post treatment 
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with gabapentin. Nine women completed the case series. In this case series gabapentin 
was found to be extremely effective in reducing hot flush activity. A significant reduction 
in symptoms was observed with a dose of 300 mg/day. In addition to an improvement in 
vasomotor symptoms measured by the Green Climacteric Scale the researchers also noted 
a statistically significant decrease in palpitations, panic attacks, muscle and joint pains 
and paresthesias. Given these findings and the fact that gabapentin was well tolerated the 
authors suggest that gabapentin could be a viable alternative for the treatment of hot 
flushes in women with contraindications to hormonal replacement therapy. 
Gabapentin was studied further by Guttuso and colleagues (2003) in a 
randomized, double-blind, placebo-controlled trial was conducted with 59 
postmenopausal women with severe vasomotor symptoms (7 or more hot flashes per 
day). Guttuso used a higher dose (900mg per day) than did Albertazzi (2003). Guttuso 
found that after 12 weeks, the intervention group treated with gabapentin 900 mg per day 
had a statistically significant over placebo of 45% reduction in hot flash frequency and a 
54% reduction in hot flash composite score (frequency and severity combined into one 
score) from baseline, compared with 29% and 31% respectively, for placebo. This study 
reflected an improvement in symptoms with gabapentin.  
The most recent study was conducted by Reddy and colleagues (2006). The 
authors found in a randomized placebo controlled trial with estrogen as a comparator that 
gabapentin was as effective as estrogen in reducing hot flashes. Both comparators 
significantly reduced hot flashes over the placebo arm. These studies suggest that 
gabapentin may be an efficacious non hormonal alternative for treating vasomotor 
symptoms. 
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COMPLEMENTARY AND ALTERNATIVE MEDICINE 
Up to this point, the review of the literature was developed from clinical research 
databases reflecting women who under treatment in a clinical setting. Yet, women who 
present to their health care providers for care because of symptoms related to menopause 
transition impart only a limited view of all women’s experiences of menopause. Many 
women, especially those who do not experience difficulties or elect not to embrace the 
biomedical paradigm of menopause may never seek help from a health care provider, 
thus their voices are lost if one only views the medical literature for answers.  
One way in which to understand what women are actually experiencing and what 
they choose to do to promote health and reduce symptoms during this midlife transition is 
to review the lay literature. A review of popular self help books and websites can 
enlighten the researcher or health care provider’s perspective of what the general public 
currently desires to know and what types of health behaviors that are being suggested to 
them. An informal internet search of “menopause” on each of the following internet book 
sites, Barnes&Noble.com, Amazon.com, Booksamillion.com and Alibris.com yielded 
over 3000 subject hits and nearly 700 book titles related to menopause. A cursory first 
look finds many titles discussing the “management” of menopause. Lyons and Griffin 
(2003) found a similar pattern in their review of 4 menopause self help books in England. 
The authors found that the much of literature embraced a medicalized viewpoint of 
menopause, in that menopause is considered a stressful event diagnosed by the medical 
professionals, yet the “management” of perimenopause/menopause falls upon shoulders 
of the women.  An example of this is found in a book aptly titled Managing your 
Menopause, by Wolfe Utian and Ruth Jacobwitz (1992).  
To shed light on the most current literature, an advance search was performed that 
was limited to current books published from 2002 forward, after the Women’s Health 
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Initiative (WHI) study findings were introduced to the health care community and the 
public. The search yielded approximately 70 books on menopause. The books reflected 
the changing times in that many titles reflected information about “truths” of hormone 
replacement (Love, 2003; Seaman, 2003) as well the experiences of 
menopause/perimenopause including some with a humorous side (Grabowski & Cheeley, 
2003; Hulem, 2003; Malucci, 1999; Sacks & Davis, 1995; Taylor & Sumrall, 1991). As 
expected numerous books are available that suggest alternatives to HT for treatment of 
vasomotor symptoms. These books provide suggestions on ways to improve health and 
wellbeing as women navigate through the menopause transition period  with the use of 
herbals, natural estrogens, or an estrogen/phytoestrogen rich diet (Gillespie, 2003; Liew 
& Ojeda, 1999; Weed, 2003), exercise (Sherman-Wolin, 2007; Smith, K., 2002),  yoga 
(Francina, 2003), mind/body (Benson, Kagan, & Kessel, 2004), homeopathy (Ikenzie & 
Akenzi, 1998; Lockie & Geddes, 1994; MacEoin, 1997), Ayurveda (Lonsdorf & Mishra, 
2002), traditional Chinese medicine (TCM), which includes acupuncture (Lu & 
Shaplowsky, 2000; Wolfe, 1992, 1994), and spirituality (Boylan, 2000; Cherry & Cherry, 
1999; Colbert, 2000; Leonetti, 2002; Sharan, 1994). The following section will provide a 
review of the various types available treatments identified in the lay literature contrasted 
with the available medical treatments within the context of current clinical research 
studies supporting or not supporting the effectiveness of these alternatives for their use in 
the treatment of menopausal vasomotor symptoms. 
Alternative Medicine Systems 
As documented earlier in this text NCCAM breaks down CAM into five 
categories; the first is Alternative medicine, which may include modalities such as 
homeopathic medicine and naturopathic medicine. The second is that of mind-body 
intervention which includes meditation, prayer, or therapies that use creative outlets such 
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as art, music, or dance. Third are biologically based “natural” therapies such as herbs, 
foods, and vitamins. Fourth are manipulative and body-based methods such as 
chiropractics or and massage. And lastly, the fifth category is labeled energy therapies, 
which would include biofield therapies such as Reiki, and Therapeutic Touch or 
bioelectromagnetic based therapies using electromagnetic fields (NCCAM, 2005). The 
review of the literature utilizes these categories in its organization. 
Traditional Chinese Medicine (TCM) 
Traditional Chinese Medicine (TCM) has been integral part of Chinese culture for 
centuries (Wolfe, 1993). Today TCM is finding its place as a compliment to Western 
medicine. TCM is a holistic process that includes a variety of approaches, including 
herbs, acupuncture and meditation to name a few. Typical TCM herbal use is done 
through a combination of individualized prescribed herbs and alternative practices. 
Clinical trials utilizing Dong Quai (Angelica sinensis) or Ginseng (Panax ginseng) each 
as a single herb have shown support for their effectiveness in treating perimenopausal 
symptoms (Kronenberg & Fugh-Berman; 2002) It is important to note here, clinical trials 
may likely not be able to measure effectiveness of TCM given its highly individualized 
treatment regimens. Davis and colleagues (2001) studied the effect of a single defined 
formula of Chinese medicinal herbs (CMH) in a study double blind randomized clinical 
trial that included 55 menopausal women from Australia. The authors found that the 
CMH formula was no better than placebo for the treatment of vasomotor symptoms in the 
women studied. 
Acupuncture 
Acupuncture is becoming more widely recognized and accepted in the United 
States. Acupuncture has to do with restoring the natural energy flow (Qi) through the 
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body.  It is postulated that the disruption of Qi is responsible for diseases (National 
Institute of Health [NIH] Consensus Development Panel, 1998). Three studies were 
located that examined at the use of acupuncture with menopausal women. All three found 
a decrease in hot flashes, although statistical significance was reached in only two of the 
studies (Dong, et al, 2001; Huang, Yael, Chen, Schnyer, & Manber, 2006; Wyon, 
Lingren, Lundeberg & Hammar, 1995). The first was a randomized trial with the use of 
either electroacupuncture as the intervention group or shallow acupuncture needle 
insertion as the control group. These researchers found a significant decrease in the 
Kupperman index (a measure of vasomotor symptoms) in both groups, but no differences 
between groups (Wyon, et al., 1995). The second study (Dong, et al., 2001) was a small 
exploratory project that used classic manual acupuncture with a group of 11 menopausal 
women. Similar to Wyon, et al, Dong and colleagues (2001) found that classic 
acupuncture resulted in a statistically significant improvement in vasomotor symptoms 
for the women studied and the effect lasted up to three months post treatment (Dong, et 
al., 2001). Huang and associates evaluated 29 menopausal women in a prospective 
randomized placebo (sham) controlled trial and found that acupuncture significantly 
reduced nocturnal hot flashes and improved sleep quality.  
These findings are very promising, yet, as with other types of  CAM modalities 
such TCM, the study of this health practice is fraught with difficulties with regard to 
study design and the use of appropriate placebo controls such as “sham” acupuncture 
(NIH Consensus Development Panel, 1998). 
Homeopathy 
Homeopathy is an alternative medical system that originated in Germany in the 
18th century. The "Law of Similars,” which is the basic principle of the therapy (Lockie 
& Geddies, 1994). Two studies were located that examined the use of homeopathy for 
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treatment of menopausal symptoms. The first was a pilot study from the United 
Kingdom. While no comparator or placebo group was included, the investigators found a 
decrease in hot flushes from baseline in the women using Homeopathy (Clover & Ratsey, 
2002). Jacobs and colleagues (2005) conducted a small (N=83) placebo controlled, 
double blind clinical trial that examined two types of homeopathy for the treatment of 
menopausal symptoms in breast cancer survivors.  The authors found that the treatment 
groups did not differ significantly from the placebo groups although there was a trend 
toward a decrease hot flashes in the treatment group. 
Ayurveda 
No clinical trials were found supporting the efficacy and safety of the use of 
Ayurveda for the treatment of menopausal symptoms. One lay text was located in the lay 
literature review (Lonsdorf & Mishra, 2002). Basically Ayurveda links menopause with 
aging. Aging is a ‘Vata’ predominant stage of life. Thus, the symptoms of menopause 
experienced by some women are similar to the symptoms seen when the Vata dosha rises 
and upsets the normal balance of the body. Vata-type menopausal symptoms tend to 
include depression, anxiety, and insomnia. Menopause may also manifest itself as a rise 
in the other two humors also. Women with Pitta-type symptoms are often angry and 
suffer hot flashes. Kapha type symptoms include listlessness, weight gain, and feelings of 
mental and physical heaviness. The type of treatment depends upon the dosha in which 
the woman's menopausal symptoms are manifesting. 
As a note of caution, Saper and colleagues (2004) reported that 1 in 5 of 
Aryuvedic herbal medicine products (HMD) may contain harmful levels of lead, mercury 
and/or arsenic.  The study findings were limited to a review of products sold within the 
Boston, Massachusetts area that had been produced in South Asia.  
 57
Mind-Body Interventions 
Stress Reduction/Applied Relaxation 
Reducing stress is important for both menopause and aging in terms decreasing 
risk of heart disease and other chronic diseases. Harvard University physician Herbert 
Benson developed and popularized a type of relaxation response that includes a simple 
meditation process that creates a sense of relaxation and stress reduction. Hoffman, 
Benson and Ans (1981) have suggested that behavioral relaxation techniques reduce 
sympathetic activity. Given the purported endocrine involvement associated with 
menopause and vasomotor symptoms it is possible that relaxation techniques that reduce 
sympathetic activity could improve vasomotor symptoms as well.  Dr. Benson has 
recently co-authored a book called Mind Over Menopause, with Leslee Kagan, M.S., 
N.P., and Dr. Bruce Kessel for as a guide for women going through this transition. A 
MEDLINE search for additional references or clinical studies from specifically the above 
referenced authors did not yield any results, but there were two studies located that 
examined the use of applied relaxation (AR) that were specific to menopausal aged 
women. 
The first Wijma, Melin, Nedstrand and Hammer (1997) published the results of a 
small pilot study including 6 women. In this study the researchers examined the 
relationship of mooed and vasomotor symptoms. They did not explore overall health. 
Participants were randomly assigned to a treatment or a control group. The intervention 
they used was a technique called applied relaxation (AR). Results indicated that this 
technique was able to lower vasomotor symptoms measured using the Kupperman Index 
but did not have an effect on mood scores.  
The second study was a randomized trial in which 12 menopausal women were 
randomly assigned to AR and 9 women to oral estrogen over a 12 week period (Nestrand, 
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Wijma, Wyon, & Hammar, 2005). Nestrand and colleagues found that although women 
in the estrogen group noted a reduction in vasomotor symptoms more quickly than the 
AR group, 11 of the 12 women in the AR group had a dramatic improvement in 
vasomotor symptoms similar to the estrogen group. In addition, the vasomotor symptom 
improvement persisted at the 6 month follow up assessment.  It is also important to note 
that both the estrogen and the AR group there was a statistically significant improvement 
over the placebo group. These two studies, although very small, begin to suggest that AR 
may help in the reduction of vasomotor symptoms, yet clearly, there is a need for larger 
more well designed studies in this area. 
Biofeedback 
Freedman and Woodward (1992) studied thirty-three women with frequent 
menopausal hot flushes who were randomly assigned to the treatment group who 
received eight sessions of training in paced respiration, muscle relaxation, or placebo 
group who underwent alpha-wave electroencephalographic biofeedback. The authors 
found a significant decrease in hot flushes in women who had the paced respiration, 
leading them to conclude that paced respiration training may be a useful treatment 
alternative for the reduction of hot flushes. 
Yoga 
Another relaxation practice that is becoming increasingly popular among all age 
groups is Yoga. Adams (2003) an OB/GYN nurse practitioner and a practicing yogini 
suggests that yoga could be highly effective for symptom relief in perimenopausal 
women. Adams believes that yoga is able to increase flexibility, decrease anxiety, 
depression and blood pressure. A general internet search found one website, 
www.hotflashyoga.com supporting the use of yoga to reduce hot flashes. A 
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MEDLINE/CINAHL literature search failed to find any references of randomized clinical 
trials directly looking at the impact of yoga on health in menopausal aged women. Again, 
as with the previously mentioned therapies, studying the varied types of Yoga available, 
the study design would be very difficult to develop. 
Biologically Based Therapies 
The intake of herbal/dietary supplements is becoming more common among 
women. Kam and colleagues (2002) found that within a group of women attending a 
health conference the majority of them had used herbal treatments for menopausal 
symptoms, of which the most common were soy, ginkgo biloba, and black cohosh.   
Soy 
Recent studies of Japanese and Chinese women who consume a soy-rich found 
that their risk of breast cancer, heart disease and experience of menopause related 
vasomotor symptoms were less than American women (Nagata 2001; Nagata, 1999). 
Given the growing awareness of the cultural disparity of the menopausal experience, 
researchers began to postulate that the typical Japanese diet high that is high in soy might 
play a part in this disparity (Adlecreutz, Hämäläinen, Gorbach & Goldin, 1992).  These 
factors have played a part in the increase interest and use of soy supplements among 
women. 
The lay literature has multiple titles touting the benefit of soy in the diet or as a 
dietary supplement (Love, 2002; Northrup, 2001; Seaman, 2003; Weed, 2002). Soy 
appears to be the most well studied dietary supplementation in terms of randomized, 
placebo controlled clinical studies. Studies on the effectiveness of soy in reducing 
vasomotor symptoms have shown conflicting results, whether soy foods (Albertazzi, et 
al., 1998;  Burke, et, al., 2003; Dalais, et al., 1998; Lewis, et al., 2006; Knight, Howes, 
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Eden, & Lowes, 2001; Murkies, et al., 1995; St. Germaine, Peterson, Robinson, & 
Alekel, 2001; Van Patten, et al., 2002) or soy isoflavone supplements (Faure, Chantre, & 
Mares, 2002; Han, Soares, Haidar, de Lima, & Baracat, 2002; Penotti, et al., 2003; 
Quella, et al., 2000;  Scambia, et al., 2000;  Uplmalis, et al, 2000) are consumed. For 
those studies showing an improvement (Albertazzi et al, 1998; Faure, et al, 2002 Han, et 
al, 2002; Scambia, et al, 2000) in menopausal symptoms the effect has been only modest.  
Unfortunately, even though many of the aforementioned studies were well designed and 
placebo controlled the amount and type of soy used as the intervention in these studies 
was varied, so a true meta-analysis is not possible. 
Beyond alleviating symptoms of menopause, evidence also exists to suggest that 
soy intake may have possible health protective effects on bones and the cardiovascular 
system (Jayagopal, et al., 2002; Lewis & Modlesky, 1998; Moeller, et al., 2003; 
Washburn, Burke, Morgan, & Anthony, 1999). In addition, Kritz-Silverstein and 
colleague’s (2003) Soy and Postmenopausal Health In Aging (SOPHIA) study suggests 
that soy isoflavone supplementation has a favorable effect on cognitive function, 
particularly verbal memory, in menopausal women. 
Black Cohosh 
The next most common dietary supplement used is Black Cohosh (Cimicifuga 
racemosa). Black cohosh is normally used by women for menstrual cramping, anxiety, 
insomnia, as well as menopausal vasomotor symptoms (Weed, 2002). This herb has 
historical use, according to the ACOG Practice Bulletin (2001); black cohosh was the 
principal ingredient in the classic early turn of the 20th century product “Lydia Pinkham’s 
Vegetable Compound,” Black cohosh has been studied most commonly using the 
standardized branded product called Remifemin®. The studies provide mixed results 
with regard to its effectiveness. Five clinical trials did not show black cohosh to be any 
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more effective than placebo in contrast to an additional two clinical trials that did find 
significant improvement in menopausal symptoms, mainly hot flashes (North American 
Menopause Society (NAMS), 2004a; Kronenberg & Fugh-Berman, 2002). Evidence 
indicates that Black Cohosh does not contain estrogenic properties (Amato, Christophe, 
& Mellon, 2002) therefore the mechanism of action is not clearly understood. 
Red Clover 
Red clover (Trifolium pretense) contains multiple phytoestrogenic compounds 
and is available as an over the counter (OTC) dietary supplement under a variety of 
names, of which Promensil® is the most common. Clinical trials for the most part have 
not found red clover to be effective in relieving symptoms in menopausal women (Baber, 
Templeman, Morton, Kelly, & West, 1999; Knight, Howes & Eden, 1999; Tice, et al., 
2003).  Although, one study with red clover (Promensil®) did find a slight improvement 
in vasomotor symptoms (van de Weijer & Barentsen, 2002). 
Evening Primrose Oil 
Evening primrose oil (Oenothera Biennis) is another commonly used product by 
women (Northrup, 2002; Weed, 2002). It has been recommended for many years by 
health care providers for a variety of uses, such as reducing breast tenderness, 
premenstrual syndrome as well as menopausal symptoms (Kronenberg & Fugh-Berman, 
2002). Evening primrose is rich in gamma linolenic acid (GLA) and is purported to 
contain anticoagulant substances (ACOG Practice Bulletin, 2001). One study was found 
by Chenoy and Colleagues (1994) that found no benefit in reducing vasomotor symptoms 
or sweating in menopausal women. In contrast, a study looking at premenstrual syndrome 
PMS), by Budeiri, Li Wan Po, & Dornan (1996) found no improvement with PMS 
symptoms, but a significant decrease in breast tenderness. 
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Vitamins/Calcium 
Calcium and vitamin D are commonly accepted and recommended for 
perimenopausal women. Supplementation with calcium (approximately 1000 mg/day in 
divided doses) can reduce bone loss in premenopausal, perimenopausal and 
postmenopausal women, especially at sites that have a high cortical bone composition. 
Vitamin D supplementation slows bone loss and reduces fracture rates in late 
postmenopausal women (Lewis & Modlesky, 1998). As for symptom relief, menopausal 
symptoms can be very similar to PMS symptoms. Clinical trials have found that for 
women with PMS calcium supplementation can effectively alleviate mood and somatic 
symptoms (Thys-Jacob, 2000). 
Manipulative and Body-Based Methods 
Only one study was located discussing the use of manipulative therapies to relieve 
vasomotor symptoms. Cleary and Fox (1994) reported that women of menopausal age 
often suffer from some form of chronic joint dysfunction that could be relieved by 
treatment with cranial osteopathy combined with Fox’s low force manipulation which 
reduces local irritations in the neurological system. Clearly and Fox postulated that given 
the relationship between the neurological and endocrine systems these manipulations may 
indeed reduce symptoms. After an initial pilot study, Clearly and Fox performed a 
placebo controlled trial with 30 participants. The placebo manipulation resembled the 
intervention manipulation of Fox’s low force manipulation, but force was delivered to an 
adjacent joint. The researchers found a significant reduction in menopausal symptoms. 
Symptom questionnaires were collected via interviews prior to treatment and at week 15.  
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Energy Therapies 
A single study was found investigating the use of reflexology to relieve symptoms 
of menopause (Williamson, White, Hart & Ernst, 2002). Williamson and colleagues 
randomized self selected participants to receive nine sessions of either reflexology or 
nonspecific foot massage (control) by four qualified reflexologists given over a period of 
19 weeks. The outcome measures utilized for vasomotor symptoms were a visual 
analogue scale (VAS) for severity of hot flashes as well as diary for frequency of hot 
flashes and night sweats. The authors found no significant differences between the 
control group and the treatment groups receiving the actual reflexology intervention.  
PHYSICAL ACTIVITY/EXERCISE 
Exercise is well accepted as an integral part of a healthy lifestyle. Exercise can 
help reduce the risk of these chronic diseases for women of any age, but the benefits can 
be significant for menopausal aged women. Exercise helps to reduce the risk of heart 
disease by enhancing cardiovascular fitness and lowering cholesterol. In addition, 
exercise can help women maintain a healthy weight. Wildman and colleagues (2004) 
found that women enrolled in the Women’s Health Lifestyle Project, a dietary and 
exercise intervention trial, experienced a slowing of menopause transition related 
atherosclerosis. 
Exercise that includes weight bearing activities such as walking and weight 
training can improve bone health. Additionally, irrespective of changes in bone mineral 
density, physical activities that improve muscular strength, endurance, and balance may 
reduce fracture risk by reducing the risk of falling (Lewis & Modlesky, 1998). 
With regard to menopausal symptoms, a study by Freedman and Krell (1999) 
found that strenuous physical activity could be a trigger for vasomotor symptoms in 
menopausal women. Gold and colleagues (2006) found no significant differences related 
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to vasomotor symptoms related to the level of physical activity the women undertake. In 
contrast evidence does exist that suggests that women who are physically active may 
actually experience less vasomotor symptoms than their inactive counterparts (Elavsky & 
McAuley, 2005; Hammar, Berg & Lindgren, 1990; Ivarson, Spetz & Hammar, 1998). 
SUMMARY 
The etiology of hot flashes is unclear, although emerging science has begun to see 
that the causes are multifaceted. Understanding the complex nature of the hot flashes and 
the recent change in HT recommendations has led to increasing amounts of research 
search for treatments for vasomotor symptoms. Although there is a call to demedicalize 
menopause, it is important to remember that the experience of menopause for some 
women can be quite bothersome. It is for these women that it is important to continue to 
strive to find ways in which to assist her through this transition. 
The ecological framework provides a means to study the varied influences upon a 
woman’s experience of menopause. The over arching macrosystems can affect the 
experience of menopause by influencing the current paradigm, be that biomedical or 
natural. In addition, high level clinical research often determines the safe practice patterns 
and attitudes of clinicians caring for women. Publication of guidelines of lay books, 
pamphlets and internet information influence women’s perceptions and beliefs as well.  
Acknowledging these levels provides for a more robust evaluation of contextual factors 
related to women’s menopausal experiences. 
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Chapter Three: Methods 
DESIGN 
In this descriptive study a retrospective, single cross sectional design was used to 
explore the vasomotor symptom experiences of postmenopausal women who have 
discontinued the use of HT. Historically, HT was prescribed for health promotion and 
chronic disease prevention and use was intended to continue for most of a women’s 
postmenopausal life.  However, as a result of several large clinical trials, perceptions 
regarding HT and HT use protocols now result in earlier discontinuation of HT. Given 
the rapidly changing standards of care for hormone therapy, little is known about how 
discontinuing HT influences women’s vasomotor symptom experiences. This study 
enriches the literature regarding this by providing initial information to fill this void.   
QUESTIONNAIRE DEVELOPMENT 
Given the diversity of women experiencing menopause, it is important to explore 
differences and similarities in the menopause experience as well as the strategies women 
use to promote health during this midlife transition.  In particular, differences in hot 
flashes emerge through cross-cultural studies.  In order to capture this diversity a 
questionnaire was created through an extensive review of the literature on the etiology of 
hot flashes, cultural influences, and contextual factors associated with the experience of 
hot flashes in women which include 1) ethnicity, 2) socioeconomic status 3) age, 4) 
length of time post menopause, 5) body mass index (height and weight), 6) type of 
menopause, 7) presence of hot flashes prior to HT use 8) severity of current hot flashes, 
9) length of HT use, 10) smoking, and 11) alcohol consumption as well as 12) 
geographical location.   
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The questionnaire was designed with 7 sections to make it more visibly appealing 
as well as to provide a clear delineation between the different areas of the questionnaire. 
The final questionnaire sections include an 1) introductory/cover letter that provides an 
overview of the study, investigator contact information and an informed consent followed 
by the data gathering sections on 2) demographic information 3) menopause history, 4) 
discontinuation influences, 5) discontinuation vasomotor experiences, 6) CAM use and 
perception and  a 7) health behavior history (see appendix 1). In addition the pilot 
questionnaire had a final section with questions about readability and understandability, 
time to complete and any other comments.  
Once the questionnaire was constructed, a group of experts involved in the care of 
menopausal women were asked to review it. This expert group consisted of 2 physicians 
(MD), 2 registered nurses (RN), and 5 advanced practice nurses (ANP), provided input 
on the general content and face validity of the questionnaire. The experts felt that the 
questionnaire was complete and did not have any additional items to add.  
PILOT STUDY 
Following expert panel review, the questionnaire was piloted to assess readability 
and comprehension in a sample of 10 menopausal volunteers. The primary goal of the 
pilot study was to gain the perspective of menopausal women with regard to ease of 
completion, readability and understandability of the questionnaire as a basis for revision, 
if needed.  
Sample 
The questionnaire was piloted with a volunteer sample of 10 women recruited via 
flyers or word of mouth. All volunteers were White with an average age of 55 years old 
with a range from 46 to 79 years. Four of the participants were married, 5 divorced and 1 
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widowed. The pilot group was very well educated with all women having at least 
completed some college credits. Eight of the participants had earned an Associates degree 
or better. Income was also high in this group with 50% of the group reporting a 
household income over $100,000 per year. The mean age at menopause onset in this 
group was 46.3 (SD 5.4). The earliest onset was age 35 and the oldest was 52. The 
majority of the participants (60%) experienced surgical menopause and 40% experienced 
natural menopause. This small group is of course too small to be representative of the all 
menopausal women, but it is very similar to the type of women who typically use HT. 
(Brennan, Crespo & Wactawski-Wende, 2004).  
The intent of the pilot study was to test the instrument for ease of completion, 
readability and understandability. The questionnaire was created as a Microsoft Word 
(MS) document that was printed out as a hard copy. The questionnaire was also designed 
to be used via email in a protected MS Word format with check boxes, drop down 
selections and text entry spaces. Five of the participants requested and completed an 
email version of the questionnaire without problems. Two participants of the 5 
participants who requested the email version had difficulty opening, saving and/or 
returning the questionnaire via email, so they subsequently requested a hard copy which 
was sent via postal mail. The problems encountered were related to type of email server 
(AOL versus MS Outlook) and a lack of computer literacy.  The 5 participants who did 
not desire the email version requested the hard copy of the questionnaire. The 
questionnaire was sent out via postal mail and was promptly returned without problems.  
The final section of the pilot questionnaire contained specific questions about the 
questionnaire’s understandability and readability: 1) How long did it take you to 
complete the questionnaire, 2) Are any of the questions hard to understand or unclear, 3) 
Are there any words contained within the questionnaire that are difficult to understand, 4) 
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Are there any experiences you had that are not shown on the questionnaire and 5) Are 
there any items that you think are not necessary or should be removed from the 
questionnaire.  
The participants indicated that it took an average of 11 minutes to complete the 
questionnaire with a range of 5 to 15 minutes. Two participants reported that the only 
term not clear to them was “Aryuvedic medicine” and one noted they were not familiar 
with the term “Homeopathy”. One participant who had requested a hard copy after 
attempting to fill out an electronic version commented that the hard copy was less 
confusing and so much easier to fill out. 
Conclusions 
Participants of the pilot study did not report any difficulty in understanding the 
questionnaire. Although two participants did not understand the terms Aryuvedic 
Medicine and one did not understand Homeopathy, the terms were not changed because it 
would appear that if the participant is unfamiliar with the term then they have not utilized 
this alternative medicine system.  
Given the difficulty of some women in completing an electronic version of the 
questionnaire, the drop down menus were removed and replaced with check boxes to 
provide a clear and easy to use hard copy version. For the larger study, the questionnaire 
was still offered electronically but participants were strongly encouraged to complete the 
hard copy version instead. 
MAIN STUDY 
Sample 
A convenience nonprobablity sample of women was recruited from September 1, 
2006 through December 31, 2006 to participate in this study.  The population of interest 
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was menopausal women over the age of 40 who had recently discontinued or taken a 
break from the use of any type of prescribed HT. For this study a minimum sample size 
of 150 participants was needed based on the “rule of thumb”. The rule of thumb indicates 
that there are at least 10 subjects per variable for correlation and logistic regression 
analysis (Knapp, 1988). There were initially 15 variables (contextual factors) for this 
study indicating that a minimum sample of 150 women was needed.  
Eligible participants were menopausal females over the age of 40 living in the 
United States, previously on prescribed HT but having discontinued or taken a break 
from prescribed HT, having the ability to read, write and speak English, and willing to 
complete the survey.  Participants were not eligible if they were not menopausal, never 
used or inconsistently used prescribed HT for less than three consecutive months prior to 
discontinuation. Returned questionnaires that were missing pertinent responses or large 
gaps of data were not included in the final analysis. Women who became menopausal as 
a result of cancer treatments were not included in the final analysis because it is known 
that cancer itself can also be a cause of hot flashes (Speroff & Fritz, 2005; Wilkin, 1981). 
Study volunteers were recruited using a variety of strategies.  The main method 
used was a mailing list, purchased from a marketing company. The mailing list was 
derived from a selection of women throughout the United States who had filled out a 
general information survey for the list owner.  The survey was a pen and paper, non-
internet based survey that the women had completed within the six months prior to 
purchase of the list for this study in the fall of 2006. The survey was not specific to 
menopause; it was a general information survey that gathered information such as survey 
respondent’s demographics, purchasing preferences and health interests. The purchased 
list was narrowed to include only women who were over the age of 40 who had noted on 
the questionnaire that they had an interest in menopause. The available demographics of 
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the list revealed that the majority of the women (61%) were married, were between the 
ages of 45 and 64 years of age (83%) and had at least a high school education (61%). The 
sample was fairly well balanced for reported income with the majority of the women 
(57%) reporting an income falling between $30,000 and $99,000. Thirty percent of the 
sample was considered to be low income reporting an income of less than $30,000 per 
year. Race data was not collected by the list owner, but ethnicity data entered by at least 
75% of the sample, revealed only 3% of the women reporting a Hispanic origin. 
Additional participants were recruited through flyers and postcards placed with 
permission at several health care provider offices, a weight loss program, and a grocery 
store in Central Texas.   In addition to providing flyers for offices of the women’s health 
care provider colleagues who provide care for menopausal women, they were also given 
the actual questionnaire to distribute to patients who fit the criteria for the study. The 
questionnaires were in a packet that included a self addressed envelope. Furthermore, 
business cards with the study overview and contact information were created and carried 
by the primary investigator to be given out to women who fit the entry criteria when the 
opportunity arose.  
The varieties of ways and settings for participant recruitment were chosen in 
hopes to promote recruitment of a more diverse sample of women than what is usually 
represented in studies related to menopause and HT.  Women who present to their health 
care providers for treatment of menopause symptoms represent only a limited view of all 
women’s experiences of menopause. Many women, especially those who may not 
experience difficulties or do not embrace the biomedical paradigm of menopause, may 
never seek help from a health care provider.  Thus their voices would be lost in this study 
if participants were recruited only from health care provider clinics.  
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As described in the previous paragraphs, in this study a small proportion of 
participants self-selected and requested the study questionnaire to be sent to them and 
another small group were identified by a health care provider as fitting the criteria for the 
study and individually recruited for the study.  However, the most of the participants 
were randomly selected from purchased mailing list and received an unsolicited 
questionnaire through the mail. Given the anonymity of the returned questionnaire it was 
impossible to identify which ones requested the questionnaire or answered and returned 
the unsolicited questionnaire.  
A mailed questionnaire was chosen because of the many advantages: ease of 
administration, relatively low cost versus personal interviews, lack of interviewer bias, 
anonymity, and opportunity to access a larger amount of participants. These advantages 
are balanced with the acknowledged disadvantages including that the respondents may 
stop the questionnaire midway through, they cannot ask for clarification, there is no 
interviewer to probe for further explanations, respondents may represent extremes and 
there is a risk of non-response bias based on the individuals who did not return the 
questionnaire.  
Additionally, mailed surveys traditionally have a low response rate.  In fact, it has 
been reported that the response rate for mailed surveys is less than 20% (Bourque & 
Fielder, 1995).  However, in this study the sampling method was very successful in 
reaching far more than the originally needed sample of 150 women.  Six hundred and 
twenty eight women returned the questionnaire resulting in an overall response rate of 
25%, which was better than expected.   
No monetary compensation was offered for the participation in the study, but the 
participants were offered an opportunity to be added to an email distribution list so that 
they can be informed of study findings. E-mail or mail notices of the completed study 
will be sent to those women who have requested a report and who had provided their e-
mail postal mail addresses to receive study findings information. 
Sample Distribution 
Twenty five hundred and fifty questionnaires were distributed to women 
throughout the US.  Of those questionnaires, 2,250 were selected randomly from the 
purchased mailing list of 4,350 using an every other person method of selection. The 
remaining 300 questionnaires were either distributed by health care colleagues or 
requested by the participant. Twelve of the 2,550 questionnaires mailed were returned as 
undeliverable. From all sources, a total of 628 completed questionnaires were returned; 
563 of these were usable. Fifty-one questionnaires were not usable because they either 
never started HT (N=35) or never stopped (N= 17) or had significant missing data 
(N=13) (see figure 3).  
Figure 3: Questionnaire distribution 
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All women who volunteered for this study received the questionnaire via postal 
mail. The questionnaire was sent in a packet that contained the questionnaire and 
preaddressed and stamped return envelope in which to return the questionnaire. No 
electronic versions of the questionnaire were used in the main study. 
Protection of Human Subjects 
This study was approved on August 29, 2006 by The Office of Research Support 
and Compliance at the University of Texas at Austin, Institutional Review Board (IRB) 
(IRB approval-IRB protocol number #2006-05-0091). Procedures to protect the subjects 
were adhered to during the entire study period.   
An overview of the study was incorporated in the questionnaire introduction.  The 
over view included the title of the study, the general purpose, how and why the 
participant was selected, study procedures, and potential risks and procedures adopted to 
minimize those risks.  The overview also provided information stating that participants 
do not have to answer all questions, and a statement describing the privacy and 
confidentiality of the participant’s responses. The participants’ name, addresses, and 
telephone number and/or email address was used only to contact them initially to mail or 
email the questionnaire to them. To provide anonymity the participant’s name, address, 
email address, return envelopes and telephone number were shredded/deleted after the 
questionnaire was sent.  Participants were also instructed that they could stop filling out 
the questionnaire at anytime or choose not to send it back without penalty if they chose to 
do so.  Consent to participate was presumed by the participants’ completion and return of 
the questionnaire.   
All data collected during the course of the proposed study is stored in a locked file 
cabinet in the principal investigator’s home office. Access is limited to the primary 
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investigator who is the only person who holds the key to the file cabinet.  All personnel 
including the primary investigator participating in this research completed the Human 
Subjects Training established by the University’s Office of Research Support and 
Compliance.  
Data Analysis 
Questionnaires were returned via US postal mail. Once the questionnaires were 
received they were opened, the envelope discarded and the questionnaire itself was 
labeled with an ID number by the primary investigator. The data from the questionnaire 
was entered into a Statistical Package for Social Sciences (SPSS, Inc, Chicago, IL) 
database created by the primary investigator.  A coding sheet was used to assist in data 
entry. After data entry, the database was reviewed for accuracy by comparing the raw 
data and running frequencies on each variable to assess for any inaccuracies in data entry 
(outliers, missing values, etc). Specific methods of statistical analysis for demographic 
variables and the research questions are reported in the following sections.  
Demographics 
Variables included in the demographic data analysis were categorical, ordinal and 
interval.  Frequency distributions and percentages were run on the following categorical 
and ordinal demographic variables: 1) current age, 2) age at menopause, 3) years post 
menopause, 4) ethnicity/race, 5) BMI range, 6)geographical location, 7) marital status, 8) 
education, 9) income and 10) type of menopause. A descriptive analysis with means and 
standard deviations (SD) also was completed on the following demographic interval level 
variables: 1) current age, 2) age at menopause, 3) years post menopause 4) BMI. 
Frequencies were also run for the aforementioned interval level variables as they were 
collapsed into ordinal level data for Chi-square analysis (χ2). Ethnicity/race was collapsed 
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into 3 categories of Black, White and other because of the limited sample of Asian, 
Hispanic, American Indian and other race/ethnicities. 
Health Behaviors 
Frequency distributions and percentages of the pertinent health behaviors that 
may have some influence on the experience of vasomotor symptoms were calculated. The 
health behaviors were: 1) type of exercise, 2) smoking and 3) alcohol use. A descriptive 
analysis with means and standard deviations (SD) also was completed for pack years of 
smoking and number of alcoholic drinks per week. 
Research aim 1: Factors influencing discontinuation of HT 
To identify factors menopausal women report that influenced their decisions to 
discontinue HT.  
Frequency distributions with percentages were completed for 1) reasons women 
gave for why discontinued HT, 2) familiarity with WHI, and 3) whether WHI influenced 
decision to stop HT.  
Research aim 2: Vasomotor symptom occurrences  
To explore the vasomotor symptom occurrences in menopausal women who have 
discontinued hormone therapy. 
In addition to demographics, vasomotor symptom occurrences of participating 
menopausal women before and after discontinuation of HT were explored. Frequency 
distributions were run for the 1) occurrence of vasomotor symptoms prior to start of HT, 
2) the occurrence of vasomotor symptoms immediately after discontinuation of HT, 3) 
continued vasomotor symptoms after discontinuation and 4) resolution of vasomotor 
symptoms after discontinuation without any intervention, 5) the severity of vasomotor 
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symptoms immediately after discontinuation and 6) the severity of vasomotor symptoms 
that continued to occur after discontinuation.   
A descriptive analysis was performed with the range, mean and standard deviation 
(SD) on 1) frequency per day of vasomotor symptoms occurring immediately after 
discontinuation and 2) the frequency per day of continued vasomotor symptoms and 3) 
time in months that it took for resolution of vasomotor symptoms without any 
intervention. 
A McNemar test was performed to assess if the participants vasomotor symptom 
occurrences prior to the use of HT differed from the vasomotor symptom occurrence after 
HT was discontinued.   
Frequency distributions with percentages were completed for the participants who 
1) restarted HT after they had discontinued, 2) indicated that they restarted because of 
vasomotor symptoms and 3) whether symptoms were either partially or full resolved after 
restarting therapy. 
Research aim 3: Contextual factors and vasomotor symptoms 
To explore the relationship between contextual factors and vasomotor symptoms 
after the discontinuation of hormone therapy  
The dependent variable is the presence of or lack of vasomotor symptoms (hot 
flashes and/or night sweats). Contextual factors that have previously been reported in the 
literature to have a possible effect on the occurrence of vasomotor symptoms represent 
the independent variables of which the majority are categorical/ordinal data with the 
exception of age, number of years post menopause and BMI. The independent variables 
include 1) current age, 2)ethnicity/race 3) education, 4) income, 5) geographical location, 
6) BMI, 7)type of menopause, 8) age at menopause, 9) years post menopause, 10) the 
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presence of vasomotor symptoms (hot flashes/night sweats) prior to initial HT use 11) 
how HT was discontinued, 12) exercise and 13) smoking and 14) alcohol intake. 
Chi-square (χ2) analysis was used to determine any statistically significant 
relationships to the dependent variable, the occurrence of vasomotor symptoms after the 
discontinuation of HT with the independent variables of ethnicity/race, education, 
income, geographical location, type of menopause, the presence of vasomotor symptoms 
prior to initial HT use, how HT was discontinued, exercise behaviors, smoking and 
alcohol intake. A Cramer’s V can be used for any size of contingency table and was run 
on all variables to assess the strength of the relationships. The Phi coefficient (φ) is 
appropriate only for a 2x2 table and is listed for variables of type of menopause, the 
presence of vasomotor symptoms prior to initial HT use, how HT was discontinued, 
smoking and alcohol intake. The Phi coefficient and Cramer’s V statistical values were 
identical, therefore for ease of reading, only the Cramer’s V was listed for all variables. 
Spearman’s Rho was run for the interval level variables of current age, age at menopause, 
years post menopause and BMI.  
Following the initial Chi-square (χ2)   and correlations, a binary logistic regression 
analysis was performed.  The dependent variable was “the presence or absence of 
vasomotor symptoms after discontinuation of HT”. This variable was entered into the 
regression model as categorical, with (1) yes had vasomotor symptoms or (0) no, did not 
have vasomotor symptoms after discontinuing HT.  
Based in part on the literature and the findings from the χ2   and correlations 8 
independent variables were chosen to be entered into the regression model. The 
independent variables in the model that were ordinal were converted to categorical 
variables as appropriate for logistic regression. Each variable was dummy coded into two 
response sets (0, 1). The following non-interval level data were dummy coded and 
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entered into the regression model as categorical variables: 1) education (high school 
education/less or college degree), 2) type of menopause (natural or hysterectomy), 3) how 
HT was discontinued (weaned or stopped suddenly), 4) vasomotor symptoms prior to 
starting HT (yes or no), 5) smoking (smokes or does not smoke), 6) alcohol intake (drinks 
alcohol or does not). Interval level data entered into the model included 7) current age 
and 8) BMI 
Variables that were not entered into the regression model included 1) the number 
of years post menopause given the redundancy of the data, as years post menopause, 
equals current age minus age at menopause.  The sample was predominantly White 
(89%) and the majority of the participants exercised (90%), therefore exercise and 
race/ethnicity were not included in the model because of the severe unequal split of the 
data responses.  Lastly, income was not included because of a large amount of missing 
data with nearly 13% of the participants failing to comment on their income.  
Type of menopause was collapsed into either natural menopause or surgical 
menopause. Medically induced menopause was not included given the sample size and 
the fact that causes of medically induced menopause such as cancer or the medical 
intervention itself may unduly influence vasomotor symptom experiences.  
Research Aim 4: Complementary and Alternative Medicine 
To identify alternative treatments that women have undertaken to treat menopause 
symptoms and their perceived efficacy. 
Frequency distributions with percentages were used to explore what types of 
alternative medical treatments and complementary and alternative medicine (CAM) 
therapies the participants had undertaken to treat their vasomotor symptoms. Frequency 
distributions with percentages were also utilized to the participants perceived the efficacy 
of their chosen method. 
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Chapter Four: Results 
DATA ANALYSIS 
Demographics 
This was not a population based survey and is not to be considered a nationally 
representative sample. However, questionnaires were received from women in every 
State in the United States except Hawaii. The geographical locations were consistent with 
the United States (US) census configurations, which breaks the US into 4 Regions 
(Northeast, Midwest, South and West).  Over 98% of participants (N=554) listed their 
geographical location. Frequency distributions revealed a fairly evenly distributed sample 
from each region of the US, with 23.8 % from the Northeast (N=132), 26.7% the 
Midwest (N=148), 31.6% the South (N=175), and 17.9% from the West (N=99) (See 
table 1).   
Study participants were primarily White (89.3%, N= 503), followed by 7.8% 
Black (N=44), 1.2% Hispanic (N=7), 1.1% Native American (N=6), 0.4% Asian (N=2) 
and 0.2% multiracial (N=1) (see table 1).  The mean age of participants was 58 years with 
a range from 40 to 82 years of age. Eligible participants who provided their weight and 
height (N=538) were included in the BMI calculation. Participants had an average BMI 
of 29.5, ranging from 16.99 to 57.76 (see table 2). 
The majority of the participants (61.5%) were married, followed by 16.2% who 
were divorced, 8.3% that were widowed, 7.5% that were single, 3.9% who reported 
partnered relationship and 2.7% who were separated.  Of the participants who reported 
their educational status (N=560), nearly 68% (N=380) held only a high school diploma or 
less. Eight percent of those women had a GED or did not complete high school. 
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Approximately 23% of the women completed an undergraduate degree and 9.2% had 
completed a graduate degree (see table 1). 
For the purposes of this study the low income cut point was chosen to reflect the 
US Department of Health and Human Services (DHHS) low-income description which is 
described as an individual whose family's taxable income for the preceding year did not 
exceed 150 percent of the poverty level amount. The 2006 poverty level was set at 
$20,000 for a family of 4 (US Department of Health and Human Services, 2006). Using a 
family unit of 4 as the US average, the low income cut point for this study was women 
who reported a total family income of less that $30,000 which is 150% of the poverty 
level for a family of 4.  
Household income information was the most frequent question that women failed 
to answer, with 72 of 563 women declining to comment on their income. Analysis 
revealed that for participants who reported their household income, 40.7% were 
considered to be low income as described previously with a total household income of 
$30,000 or less.  Slightly greater than 36% of the participants fell into a middle income 
range between $30,001 and $60,000. Fourteen and a half percent of the participants fell 
into the middle upper income range reporting income between $60,001 and $80,000 and 
in the upper income range, 8.4% reported an income of $90,001 or above (See table 1).   
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Table 1: Demographic information (categorical and ordinal) 
Characteristic N (%) Familiar with 
WHI 
 VMS prior to 
using HT 
VMS  after HT 
discontinued 
 Restarted HT Used alternative 
and/or CAM  
Current Age1         
40-50 years old 59 (10.6%) 9 (15%)  43 (72.9%) 55 (93.2%)  12 (20.3%) 33 (55.9%) 
51-60 years old 298 (53.8%) 64 (21.5%)  231 (77.5%) 250 (83.9%)  44 (14.8%) 147 (49.3%) 
61 years old or over 197 (35.6%) 42 (21.3%)  143 (72.5%) 141 (71.6%)  23 (11.7%) 70 (35.5%) 
 
Age at Menopause2 
        
39 years old or under 103 (18.5%) 18 (17.5%)  68 (66.0%) 91 (88.3%)  18 (17.5%) 58 (56.3%) 
40-50 344 (53.8%) 73 (21.2%)  264 (76.7%) 277 (80.5%)  51 (14.8%) 144 (41.9%) 
51-60 or older 110 (19.8%) 26 (23.6%)  86 (78.2%) 81 (73.6%)  11 (10.0%) 48 (43.6%) 
 
Years Postmenopause3 
        
1 year or less      7 (1.3%) 0 (0%)  5 (71.4%) 6 (85.7%)  1 (14.3%) 4 (57.1%) 
More than 1 year to 5 years 77 (14.1%) 21 (27.3%)  65 (84.4%) 70 (90.9%)  14 (18.2%) 48 (62.3%) 
More than 5 years to 10 years 145 (26.5%) 32 (22.1%)  115 (79.3%) 111 (76.6%)  16 (11.0%) 60 (41.4%) 
More than 10 to 20 years 216 (39.4%) 46 (21.3%)  160 (74.1%) 172 (79.6%)  32 (14.8%) 92 (42.6%) 
More than 20 years 103 (18.8%) 16 (15.5%)  67 (65.0%) 83 (80.6%)  16 (15.2%) 44 (42.7%) 
 
Ethnicity/Race 
        
Black  44 (7.8%) 9 (20.5%)  34 (77.3%) 41 (93.2%)  2 (4.5%) 21 (47.7%) 
White 503 (89.3%) 107 (21.3%)  379 (75.3%) 401 (79.7%)  78 (15.5%) 227 (45.1%) 
Other 16 (2.8%) 1 (6.3%)  10 (62.5%) 11 (68.8%)  0 (0%) 4 (25.0%) 
Asian 2(0.4%)         
Hispanic 7(1.2%)         
Native American 6 (1.1%)         
Mixed 1 (0.2%)         
 
BMI ranges4 
        
Underweight (<18.5) 16 (3.1%)   12 (75.0%) 12 (75.0%)  2 (12.5%) 11 (68.8%) 
Normal range (18.5-24.9) 138 (27.1%)   105 (76.1%) 112 (81.2%)  30 (21.7%) 72 (52.2%) 










N (%) Familiar with 
WHI 
 VMS prior to 
using HT 
VMS  after HT 
discontinued 
 Restarted HT Used alternative 
and/or CAM  
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Characteristic 
Region5         
Northeast 132(23.8%) 30 (22.7%)  101 (76.5%) 106 (80.3%)  18 (13.6%) 57 (43.2%) 
Midwest 148(26.7%) 33 (22.3%)  108 (73.0%) 121 (81.8%)  23 (15.5%) 75 (50.7%) 
South 175(31.6%) 26 (14.9%)  134 (76.6%) 144 (82.3%)  24 (13.7%) 77 (44.0%) 
West   99(17.9%) 25 (25.3%)  73 (73.7%) 75 (75.8%)  15 (15.2%) 41 (41.4%) 
 
Marital Status 
        
Single 42(7.5%)        
Partnered 22(3.9%)        
Married 346(61.5%)        
Separated 15(2.7%)        
Divorced 91 (16.2%)        
Widowed 47(8.3%)        
 
Highest level of Education6 
        
HS Diploma (or less) 380 (67.9%) 48 (12.6%)  291 (76.6%) 304 (80.0%)  53 (13.9%) 172 (45.3%) 
Undergraduate Degree 128 (22.9%) 36 (28.1%)  92 (71.9%) 108 (84.4%)  21 (16.4%) 57 (44.5%) 
Graduate Degree 52 (9.2%) *32 (61.5%)  37 (71.2%) 38 (73.1%)  6 (11.5%) 23 (44.2%) 
 
Family income7 
        
<$30,000 (low income) 200(40.7%) 24 (12.0%)  151 (75.5%) 156 (78.0%)  20 (10.0%) 86 (43.0%) 
$30,001-$60,000 (middle income) 179(36.5%) 36 (20.1%)  144 (80.4%) 150 (83.8%)  26 (14.5%) 83 (46.4%) 
$60,001-$90,000 (middle/upper) 71(14.5%) *26 (36.6%)  50 (70.4%) 58 (81.7%)  15 (21.1%) 32 (45.1%) 
>$90,001 (high income) 41(8.4%) *14 (34.1%)  27 (65.9%) 31 (75.6%)  9 (22.0%) 19 (46.3%) 
 
Type of menopause8 
        
Natural 358(63.9%) 81 (22.6%)  293 (81.8%) 275 (76.8%)  44 (12.3%) 154 (43.0%) 
Surgical 193(34.5%) 35 (18.1%)  120 (62.2%) 167 (86.5%)  34 (17.6%) 90 (46.6%) 
Medical 9(1.6%) 1 (11.1%)  7 (77.8%) 8 (88.9%)  1 (11.0%) 6 (66.7%) 
1Missing data for current age for 9 participants, posted percentages represent valid responses only 
2Missing data for age at menopause for 15 participants, posted percentages represent valid responses only 
3Missing data for years post menopause for 15 participants, posted percentages represent valid responses only 
4Missing data for years post menopause for 15 participants, posted percentages represent valid responses only 
5Missing data for geographical location for 5 participants, posted percentages represent valid responses only 
6Missing data for educational level on 3 participants, percentages represent valid responses only 
7Missing data for income for 72 participants, percentages represent valid responses only 
8Missing data on type of menopause for 3 participants, percentages represent valid responses only 
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The mean age for the onset of menopause of the participants was 45 years of age. 
The earliest onset was age 20 and the oldest was 61. The mean years post menopause for 
the participants was approximately 14 years with a range from less than a year up to 45 
years (see table 2). Five hundred and sixty women reported the type of menopause they 
experienced, the majority of them (63.6%) experienced natural menopause (N=358), 
34.3% experienced surgical menopause (N=193) and 1.6% reporting medically induced 
menopause (N=9). (See table 1). According to the Center for Disease Control (CDC) July 
2002 Morbidity and Mortality Weekly Report (MMWR) from 1994 through 1999, one in 
every nine women aged 35-45 years had a hysterectomy. The respondents to this study 
had a 3 times higher rate of hysterectomy than what is reflected in this report. 
 
Table 2: Demographic information (interval) 
 
Characteristic Minimum Maximum Mean Std Deviation 
Current Age1 40 82 58.74 6.99 
Age at menopause2 20 61 44.99 7.56 
Years post menopause3 0 45 13.69 8.18 
Body Mass Index (BMI)4 16.99 57.16 29.55 7.35 
1Missing data for current age on 9 participants, posted statistics represent valid responses only 
2Missing data for age at menopause on 6 participants, posted statistics represent valid responses only 
3Missing data for years post menopause on 15 participants, posted statistics represent valid responses only 
4Missing data on BM on 25 participants, posted statistics represent valid responses only 
 
 
Health behaviors assessed included exercise, smoking habits and alcohol intake. 
Surprisingly, 10% of the participants reported that they did not exercise at all. Just over 
50% of the women reported exercising mildly which was described as climbing stairs, 
walking 3 blocks, golf). Eighteen percent of the women listed their exercise as moderate 
(30 minutes of vigorous activity less than 4 times per week and 20.6% women reported 
vigorous activity for at least 30 minutes more than 4 times per week (see table 3). Eighty 
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percent of the women reported that they did not smoke (see table 3), conversely 20% of 
women reported smoking with an average of 32 pack years (see table 4). Pack years is 
calculated by the number of packs per day x the number of years smoked. Nearly 42% of 
women reported no alcohol intake at all, while 58% of women (see table 3) reported an 
average intake of approximately 3 drinks per week (see table 4), primarily wine (77.2%), 
followed by beer (13.5%) and hard liquor (8.8%). 
 
Table 3: Health Behaviors (categorical, ordinal) 
Characteristic N (%) Vasomotor symptoms 
Exercise1  
No exercise 60 (10.8%) 47 (78.3%) 
Mild exercise 279 (50.1%) 223 (79.9%) 
Occasional vigorous exercise 101 (18.1%) 81 (80.2%) 
Regular vigorous exercise 115 (20.6%) 94 (81.7%) 
Smoker2  
Yes 107 (19.3%) 89 (84.0%) 
No 449 (80.8%) 356 (79.3%) 
Alcohol use3  
Yes 232 (41.9%) 194 (83.6%) 
No 322 (58.1%) 250 (77.6%) 
1Missing data on type of exercise for 7 participants, percentages represent valid responses only 
2Missing data on smoking for 7 participants, percentages represent valid responses only 
3Missing data on alcohol use for 9 participants, percentages represent valid responses only 
 
Table 4: Health behaviors (interval) 
Characteristic Minimum Maximum Mean Std Deviation 
Smoking pack years 0 132 32.54 23.76 
Alcohol (drinks/week) 0 24 3.24 3.71 
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Research aim 1: Factors influencing discontinuation of HT 
To identify factors menopausal women report that influenced their decisions to 
discontinue HT.  
Participants were asked to select all the factors that influenced their decision to 
discontinue HT. Forty one percent of the respondents indicated that they stopped HT 
because of the information they received about HT (see table 5). The majority of the 
women indicated that their primary source of this information was in the form of written 
publication (21.3%), followed by television (14%) and internet (6.2%). 
The second most common reason women (33.2%) selected was because their 
health care provider recommended that they discontinue (see table 5). Participants 
reported several reasons why their health care provider recommended discontinuation.  
Some health care providers recommended because of certain health conditions such as 
hypertension, headaches, leg pains or swelling. Some of the participants discontinued HT 
when they had an extended hospitalizations or surgery, and others were stopped via their 
healthcare provider’s suggestion because of a family history of breast cancer.  Many of 
the participants reported that their health care provider suggested the discontinuation of 
HT because of new information about HT. The reported new information that the 
included comments such as a suggested link to an increase risk of breast cancer, an 
increased cardiovascular risk and stroke, no benefit for cardiovascular disease, and that 
the newly recommended shorter length of use of HT than previously recommended.  In 
addition many of the participants reported that their health care provider recommended 
they discontinue HT without any providing any specific reason to do so.  
The third most common response that nearly 25% of women indicated was a 
reason they discontinued was because they were afraid of the increased risk of breast 
cancer. Following this many women reported that they simply stopped HT to test how 
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they would feel off of HT (19.9%). A similar number of women also reported that they 
feared the occurrence of a blood clot or stroke (19.4%). Fourteen percent of women 
reported that they discontinued HT because of non-life threatening side effects such as 
breast tenderness, irregular bleeding, swelling in the extremities, heart palpitations, 
nausea, weight gain, polyps, dizziness and mood swings. Thirteen percent of the 
participants stopped HT after experiencing a serious life threatening side effect such as a 
thrombembolic event, stroke, cancer or heart attack. The less common reasons for 
discontinuation were the cost of the prescription (8.5%), to try another type of treatment 
(5.7%), no specific reason (5.3%), friend or coworker suggested (3.2%), husband or life 
partner recommended (2.5%), HT did not relieve symptoms (1.8%), pharmacist 










Table 5: Reasons for discontinuation of HT 
Reasons for discontinuation of HT N (%) 









Health care provider recommended 187 (33.2%) 
 
Afraid of the risk of breast cancer      140 (24.9%) 
 
Stopped on own to see how felt off of HT 112 (19.9%) 
 
Afraid of the risk of blood clot or stroke 109 (19.4%) 
 
Side effects 79 (14.1%) 
 
Serious life threatening side effects 73 (13%) 
 
Because of the cost of the prescription 45 (8.5%) 
 
To try another type of treatment 32 (5.7%) 
 
Stopped on own for no particular reason 30 (5.3%) 
 
Friend or coworker recommended 18 (3.2%) 
 
Husband or life partner recommended 14 (2.5%) 
 
No relief of symptoms 10 (1.8%) 
 
Pharmacist recommended 5 (0.9%) 
 
Felt was on HT too long 5(0.9%) 
 
Despite the high percentage of women who discontinued HT based on 
information they read or received from their health care provider (see table 5), only 20% 
(N=117) of the participants indicated that they were actually familiar with a study 
specifically called the Women’s Health Initiative (WHI). Of those women that were 
familiar with the study and had discontinued HT in the year 2002 or after (N=111), only 
40% of them indicated that the findings did influence their decision to discontinue HT. 
Women who were aware of the WHI were statistically significantly (χ2) more likely to 
 88
have an income above $60,000 and had completed a graduate degree than the women 
who indicated they were not familiar with the study (see table 1). 
Research aim 2: Vasomotor symptom occurrences  
To explore the vasomotor symptom occurrences in menopausal women who have 
discontinued hormone therapy. 
Seventy five percent of the study participants reported the occurrence of 
vasomotor symptoms prior to the initial start of HT. In contrast, 80% reported the 
occurrence of vasomotor symptoms after discontinuation of HT.  The women who 
experienced vasomotor symptoms immediately after discontinuation reported upon the 
severity of their symptoms, of which 21.1% stated their symptoms were mild, 32.7% 
moderate, and 23.2% were reported as severe (see table 7). The frequency of vasomotor 
symptoms occurring immediately after discontinuation ranged from less than 1 to a 
maximum of 30 vasomotor symptoms per day with a average frequency of approximately 
5 per day (see table 7). 
 
Table 6: Vasomotor experiences (categorical, ordinal) 
Vasomotor Symptoms (VMS) N (%) 
Experienced VMS before started HT 423 (75.1%) 
Experienced VMS immediately after discontinued HT 453 (80.5%) 
Severity of VMS immediately after discontinuation       Severe       131 (23.2%) 
Moderate   184 (32.7%) 
        Mild          119 (21.1%) 
Continued to have VMS after discontinuation 320 (56.8%) 
Severity of continued VMS Severe        39 (6.9%) 
Moderate 105(18.7%) 
 Mild       138 (24.5%) 
VMS resolved without any intervention 215(38.2%)
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Thirty eight percent of the participants reported that their vasomotor symptoms 
resolved spontaneously without any intervention. For those women whose symptoms had 
resolved the time frame ranged from immediately upon discontinuation up to 2 ½ years 
with an average resolution time of approximately 5 months. Almost 57% of the 
participants continued to have vasomotor symptoms. A closer look at the symptoms of 
this women demonstrated that the vasomotor symptoms decreased over time. The percent 
of women having severe symptoms immediately after discontinuation decreased from 
23.2% to 6.9%, and moderate symptoms went from 32.7% to 18.9% (see table 6). The 
range of the frequency of symptoms remained similar at 0 to 30 per day although the 
average decreased from 5 to 3 per day (see table 7). 
 
Table 7: Vasomotor symptom frequencies/resolution (interval) 
Vasomotor Symptoms   Min Max Mean Std Deviation 
Frequency/day of VMS immediately after 
discontinuation 
 
0.5 30 4.96 4.807 
Frequency/day of continued VMS con 
 
0.5 30 3.41 3.488 
Months to resolve VMS 0 354 4.99 24.071 
 
As noted earlier, fewer women experienced vasomotor symptoms prior to HT 
initiation (N=423) than after discontinuation of HT (N=453).  To determine if there was 
significant difference between vasomotor symptoms prior to and those immediately after 
discontinuation, a McNemar test was conducted. The test revealed that the occurrence of 
vasomotor symptoms prior to the initiation of HT was significantly different (<.05) than 
the occurrence of vasomotor symptoms after the discontinuation of HT.  
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Women who were Black, between the ages of 40-50, experienced menopause 
before age 40, were less than 5 years post menopause tended to report more vasomotor 
symptoms after discontinuation of HT than prior to their use of HT (See table 1). 
Fourteen percent of the participants (N=82) restarted HT after they had 
discontinued. Of those women, approximately 80% (N=66) indicated that they restarted 
because of vasomotor symptoms. Ninety two percent (N=61) of the women who restarted 
HT because of vasomotor symptoms reported that their symptoms were either partially or 
full resolved after restarting therapy. Women who restarted HT were more likely to be 
White, between the ages of 40 and 50, less than 5 years post menopause onset, had at 
least a graduate degree, and experienced surgical menopause (See table 1). 
Participants who had not restarted therapy were asked if they planned to do so in 
the future. They were given 4 response sets: 1) no, 2) yes, 3) not sure or 4) awaiting more 
information. The majority of the women (67%) indicated that they would not restart HT. 
Although, twelve percent of the women indicated they were not sure at this time and 5% 
reported that they were still awaiting more information before they made the decision to 
restart. 
Research aim 3: Contextual factors and vasomotor symptoms 
To explore the relationship between contextual factors and vasomotor symptoms 
after the discontinuation of hormone therapy  
Chi-square analysis (χ2) of categorical and ordinal level contextual factors of was 
conducted with the following variables: ethnicity/race, education, income, geographical 
location, menopause type, presence of vasomotor symptoms prior to initial HT use, how 
HT was discontinued, exercise behaviors, smoking and alcohol intake. Given the small 
number of participants of Asian, Hispanic, American Indian or other, ethnicity/race was 
collapsed into three categories of Black or White or Other (Asian, Hispanic, American 
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Indian or other). Education was collapsed into three categories high school education or 
less, undergraduate degree or graduate degree.  
Chi-square analysis revealed that ethnicity (p=0.047), type of menopause 
(p=.019) and the presence of vasomotor symptoms prior to beginning HT initially 
(p=.000) were significantly related to the dependent variable, vasomotor symptom 
occurrence. For two of the variables, Cramer V’s statistics revealed that the relationships 
were fairly weak for ethnicity (.104) and type of menopause (.119). However, vasomotor 
symptoms prior to HT initiation revealed a moderate association (.027). (see table 8). 
 
Table 8: Relationship (χ2) of ordinal level contextual variables and VMS 
Characteristic Cramer’s V Significance 
Ethnicity .104  .047 
Education .074  NS 
Income .074  NS 
Geographic location .059  NS 
Type of menopause .119  .019 
VMS prior .276  .000 
How HT discontinued .001  NS 
Exercise .027  NS 
Smoking .048  NS 
Alcohol use .074  NS 
  
Correlations were run with a Spearman Rho test set at the .05 significance level 
for the interval level variables of current age, BMI, age at menopause and years post 
menopause. Analysis revealed a significant inverse relationship between the dependent 
variable (vasomotor symptoms post discontinuation), and the variables of current age and 
age at menopause. These results indicated that younger current age and younger age at 
menopause onset were statistically associated with a higher occurrence of vasomotor 
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symptoms after the discontinuation of HT, however the relationships for both variables 
were weak (see table 9).  
Table 9: Relationship (Spearman Rho) of interval contextual factors and VMS 
Characteristic Spearman’s Rho  Significance 
Current Age -.180 .000* 
BMI -.035 NS 
Age at menopause -.110 .009* 
Years post menopause -.059 NS 
 
To assess further the combined influence of contextual factors on the independent 
variable of vasomotor symptom occurrence a logistic regression was performed. The 
dependent variable, vasomotor symptoms after discontinuation of HT was entered into 
the model as categorical, with yes (1), had vasomotor symptoms or no(0), did not have 
vasomotor symptoms after discontinuing HT. In order to conduct logistic regression 
analysis all ordinal independent variables were converted to categorical variables. The 
variables were dummy coded into two response sets (0, 1).  
Based on findings in the literature and the results of χ2 and Spearman Rho 
correlations the following independent variables appeared to be useful to the model and 
were entered into the regression model. Categorical variables included 1) education (high 
school education/less or college degree), 2) type of menopause (natural or hysterectomy), 
3) how HT was discontinued (weaned or stopped suddenly), 4) vasomotor symptoms 
prior to HT (yes or no), 5) smoking (smokes or does not smoke), 6) alcohol intake 
(drinks alcohol or does not). The interval level variables entered into the model included 
7) current age and 8) BMI 
Variables not included in the model were 1) ethnicity/race, 2) income, 3) 
geographical location, 4) exercise, 5) age at menopause and 6) years post menopause. 
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Although variable of ethnicity/race has been shown in the literature to be associated with 
vasomotor symptom experiences and revealed significance in the initial χ2 it was not 
included because of the severe split in the data (89% White, 7.8% Black, and 2.8% 
other). The variable of exercise was not included in the model because of a bad split in 
the data as well, with the overwhelming majority of the women (90%) exercising versus 
no exercise (10%). Income was removed from the model because of a significant amount 
of missing data; this question was the most common question that went unanswered. 
Thirteen percent of the participants declined to enter a response for income.  Finally, 
given the redundancy of the data, in that years post menopause equals current age minus 
age at menopause, only current age was entered into the model. In addition current age 
reporting ensures better accuracy in the data then a retrospective report of age at 
menopause. 
Simple logistic regression model with all of the aforementioned variables entered 
into the model summary revealed a Cox and Snell R2 statistic of 0.128 indicating that the 
combined independent variables accounted for only 13% of the total variance of 
vasomotor symptoms occurrence (table 10).  
With a 0.5 criterion for statistical significance, three of the eight predictor 
variables entered into the model had a significant partial effect on the model, although the 
strength of the effect was relatively small. Those variables were the presence of 
vasomotor symptoms prior to initial start of HT (p=.000), type of menopause (p=.000), 
and current age (p=.001) (see table 10). 
The presence of vasomotor symptoms prior to starting HT when all other 
variables were held constant had a negative B statistic and odds ratio of .179, indicating 
that if vasomotor symptoms were absent prior to the initial start of HT it is likely they 
will be absent after discontinuation of HT as well. Type of menopause had a positive B 
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statistic with an odds ratio 2.92 indicating that women who have had a hysterectomy are 
3 times more likely to experience vasomotor symptoms after discontinuation of HT.  For 
current age with all the other variables were held constant the regression model revealed 
a negative B statistic with an odds ratio of .942 suggesting that the older the current age 
of the woman, the less likely she would experience vasomotor symptoms after 
discontinuation of HT.   
Table 10: Regression analysis: Contextual factors to predict presence of vasomotor 
symptoms 
 Predictor Variable B Wald Sig Odds ratio 95% CI 
      Lower        Upper 
Educational level .087 .110 NS 1.091 .651 1.828
Type of Menopause 1.07 13.76 .000 2.920 1.658 5.142
How HT was discontinued -.002 .00 NS .998 .589 1.693
VMS symptoms prior to HT -1.71 43.07 .000 .179 .107 .300
Smoke .10 .10 NS 1.11 .587 2.108
Alcohol intake -.46 3.27 NS .629 .381 1.039
Current age -.06 11.38 .001 .942 .910 .975
BMI -.02 1.38 NS .981 .949 1.013
 
Research aim 4: Complimentary and Alternative Medicine 
To identify alternative treatments that women have undertaken to treat menopause 
symptoms and their perceived efficacy. 
Of the 563 study participants, less than half (N=252) reported the use of an 
alternative treatment to treat vasomotor symptoms. Women who were between the ages 
of 40-50, less than 5 years post menopause onset, and experienced medical menopause 
were more likely to utilize alternative treatments (see table 1).  
Beginning with the most common choice of alternative methods used were 1) 
multivitamins and calcium (59.2%), 2) Black Cohosh (46.4%), 3) Soy supplements and 
food (42.4%), 4) antidepressants (32%), 5) meditation and relaxation (26%), 6) Evening 
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Primrose Oil (17.2%), 7) Other (15.1%), 8) blood pressure medications (13.7%), 9) 
Homeopathy (12.4%), 10) Red Clover (7.6%), 11) anti-seizure medications (8.4%), 12) 
bio-identical hormones (6.4%), 13) Traditional Chinese Medicine (2.8%), 14) 
Acupuncture (2.4%), 15) Aryuvedic Medicine (0.2%). In the “other” category note 
above, the use of Estroven, Flaxseed, or Progesterone cream was listed by 5 women. New 
Phase and St. Johnswort was listed by 2 women and the use of Bellergal, Colchicines, 
Echinacea, Estro-life, GNC Menopause, Phyto Prolief Arborne, and Valerian were 
reported by at least 1 woman (see table 11).  
Table 11: Alternative Treatments for vasomotor symptoms 
Alternative Treatment Utilized treatment N (%) Perceived Efficacy N (%) 
Alternative Medicine Systems 
Acupuncture 6(2.4%) Helped 








Aryuvedic Medicine 1(0.4%) Helped 








Homeopathy 31(12.4%) Helped 








Traditional Chinese Medicine 7(2.8%) Helped 








Biologically based therapies 
 
Black Cohosh 116(46.4%) Helped 







Evening Primrose Oil 43(17.2%) Helped 








Soy supplements/food 106(42.4%) Helped 
Did not Help 
Not sure 






Alternative Treatment Utilized treatment N (%) Perceived Efficacy N (%) 
 
Red Clover 19(7.6%) Helped 











Multivitamins/Calcium 148(59.2%) Helped 








Other listed alternatives: 
 
38(15.1%) Helped 








Mind Body Methods 
 
Meditation/Relaxation 65(26%) Helped 








Yoga 26(10%) Helped 







Alternative Western Medical Treatments 
 
Antidepressants 80(32%) Helped 








Antiseizure medications 21(8.4%) Helped 








Blood pressure medications 34(13.7%) Helped 








Women were asked to comment on whether the method helped, did not help or if 
they were unsure if it helped. Given the relatively small numbers of women using some 
of the methods, assessment of what was the most efficacious method of all is not feasible. 
There were 8 alternative therapies that were used by at least 30 women which were 
 97
multivitamins and calcium, Black Cohosh, Soy supplements and food, antidepressants, 
meditation and relaxation, evening primrose oil, Homeopathy and blood pressure 
medications. Of these the participants perceived antidepressants as one of the most 
efficacious method with 55% of the 80 women saying that it helped their symptoms, 
followed by Homeopathy (46.7%), meditation and relaxation (41.9%), evening primrose 
(38.5%), blood pressure medications (35.2%), Black Cohosh (33.9%), soy products 
(32%), and multivitamins and calcium (25.2%). (See table 11).  
 Of the methods less frequently identified, 21 women utilized anti-seizure 
medications, of those 21 women, only 4 (19.1%) women reported that they felt it helped, 
next was red clover which was used by 19 women, 8 (50%) of which felt it helped. Next 
was bio-identical hormones which were used by 16 women, of which 7 (43.7%) of them 
felt they helped. Seven women chose Traditional Chinese Medicine (TCM) and 4 
(57.1%) of them felt TCM helped their symptoms. Six women tried Acupuncture and 3 
(50%) of them felt it helped their symptoms. One woman reported using Aryuvedic 




Chapter Five:  Discussion 
This study contributes to the literature on HT discontinuation experiences of 
menopausal women. This study was not a population based sample nor was not ethically 
or racially diverse, yet, data was captured from a unique group of menopausal women. 
The women in this study were not a clinic based sample, and there was a lower 
educational and income status that are not usually a part of menopause and HT related 
studies.  
Demographics 
This was not a population based survey and is not to be considered a nationally 
representative sample. However, questionnaires were received from women in every 
State in the United States except Hawaii. Not all States were equally represented in the 
sample, although the women were fairly well equally distributed throughout the United 
States census defined regions (Northeast, Midwest, South and West). The participants 
were predominantly White, married and of lower socioeconomic status. Interestingly, the 
sampling procedure resulted in a sample which included women who are often not 
represented in menopause research. One unique aspect of this sample was that the 
majority of the participants reported their highest level of education being a high school 
diploma. Also, participants reported lower income levels than is usually recruited with 
nearly 40% of the sample reporting income of less than $30,000 per year.  The lack of an 
ethnically and racially diverse sample that was representative of the US population was 
not totally unexpected. What was most impressive with this sample was the ability to 
capture a group of menopausal women with a lower educational and income status. Not 
only is it more likely that studies with menopausal women usually reflect a sample that is 
predominantly White and of higher socioeconomic status, the literature also tells us that 
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these same women are more likely to see a health care provider for menopause and to be 
prescribed and take HT (Brennan, Crespo& Wactawski-Wende, 2004).  
RESEARCH AIM 2: VASOMOTOR SYMPTOM OCCURRENCES 
Ockene and colleagues (2005) found that nearly half of the participants who had 
reported vasomotor symptoms at baseline also experienced vasomotor symptoms 
following discontinuing treatment and this had a great impact on whether a woman was 
able to stop HT successfully without unbearable symptoms. This study does provide 
some support for the Ockene findings (2005), yet the current study found that slightly 
more women experienced vasomotor symptoms after discontinuation of HT versus prior 
to initiation. A McNemar test comparing the two groups revealed that difference was 
statistically significant which may suggest the difference in the occurrence of vasomotor 
symptoms at menopause onset prior to HT use is perhaps a different phenomenon than 
the vasomotor symptoms experienced immediately after discontinuation of HT. It is also 
possible that this finding may be a result of a recall bias due to the fact that the vasomotor 
symptoms experienced before the start of HT occurred much further in the past than the 
current experiences of HT after recent discontinuation. 
Participants who reported more vasomotor symptoms after discontinuation of HT 
than prior to their use of HT were more likely to be Black, between the age of 40-50, 
experienced menopause before age 40,  and were less than 5 years post menopause. 
These findings related to current age, age at menopause and years post menopause is not 
surprising and rather intuitive, as it is known that vasomotor symptoms have been shown 
to decrease over time in most women (Speroff & Fritz, 2005). Women who experienced 
surgical menopause also reported a greater occurrence of vasomotor symptoms after 
discontinuation of HT than prior to. These findings are not surprising; research has shown 
that women who experience surgical menopause tend to have a higher incidence of 
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vasomotor symptoms and they are likely to be more severe (Chakravarti, et al., 1977; 
Feldman, Voda, & Gronseth, 1985; Speroff & Fritz, 2005). This is also consistent with 
studies looking at this after discontinuation of HT. Grady and colleagues (2003) found 
that the factors that were most highly associated with the inability to stop hormone 
therapy were hysterectomy and duration of hormone use of over 10 years.  
Fourteen percent of the participants restarted HT after discontinuation. Of those 
women, approximately 80% (N=66) indicated that they restarted because of vasomotor 
symptoms. This finding is higher than what Ockene and colleague (2005) found in their 
study. They found that only 5% of the women in their study restarted HT with the 
primary reason to treat vasomotor symptoms. In contrast Grady and colleagues (2003) 
found that nearly 25% of the women in their study who had discontinued HT, restarted 
because of vasomotor symptoms.  
RESEARCH AIM 3: CONTEXTUAL FACTORS AND VASOMOTOR SYMPTOMS 
One primary purpose in this study was to explore the relationship between 
contextual factors and vasomotor symptoms after the discontinuation of hormone 
therapy.   Initial analysis began with a χ2 and Spearman’s Rho correlations to ascertain 
which factors, if any, were related to the occurrence of vasomotor symptoms after 
discontinuation of HT. Significant variables indicated in the initial analysis in addition to 
variables indicated from the literature review were entered into the logistic regression 
model. In the resulting model, the significant contextual factors associated with the 
reoccurrence of vasomotor symptoms after discontinuation of HT were the presence of 
vasomotor symptoms prior to initial start of HT (p=.000), type of menopause (p=.002), 
and current age (.001). With the exception of current age, these findings are quite 
consistent with other studies that have looked at HT discontinuation experiences.  
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Grady and colleagues (2003) identified characteristics in women that would make 
it more difficult for them to discontinue HT.  Similar to the current study, the authors 
found that women who had had a hysterectomy were the least likely to successfully 
discontinue HT without recurrence of vasomotor symptoms. They also found no 
significant association of symptoms with contextual factors of age, ethnicity, education, 
BMI and smoking.  
Ockene and colleagues (2005) explored menopause symptom experiences of 
women who had recently participated in the estrogen and progestin treatment arm of the 
WHI study. They found that the strongest determinant of vasomotor symptoms after 
discontinuation of HT was the presence of vasomotor symptoms at baseline even after 
adjusting for age, BMI, alcohol and tobacco use. Consistent with these findings, Grady, et 
al (2005) and Hammar, et al (2003), found that women who did not have vasomotor 
symptoms prior to treatment were less likely to experience vasomotor symptoms after 
withdrawal of HT. The current study found a similar relationship with the occurrence of 
vasomotor symptoms prior to HT.  There was an increased likelihood of the occurrence 
of vasomotor symptoms after discontinuation of HT if there were vasomotor symptoms 
prior to the start of HT.  
All three of the discontinuation studies (Grady, et al, 2003; Hammar, et al, 2003; 
Ockene, 2005) found that that tapering off of HT was no more affective then stopping 
abruptly in preventing the occurrence of vasomotor symptoms. The current study findings 
are consistent with these studies. The samples for both Grady et al (2003), and Ockene et 
al (2005) were predominantly White and had a higher educational status than the women 
in the current study.  
In contrast, studies examining the varied vasomotor symptom experiences of 
women at menopause onset and prior to the initiation of HT  have shown  that 
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socioeconomic status, ethnicity/race, body weight, smoking, alcohol intake, type of 
menopause and years post menopause do influence symptom experiences. In the current 
study, lack of ethnic/racial diversity precluded examining group differences.  However, 
no significant relationships were found with body weight (BMI), smoking or alcohol 
intake.  Socioeconomic status was evaluated by proxy measure of educational status only 
and was non-significant.  These findings contrast with factors identified as significant 
prior to initiation of HT.  Further examination of these differences is needed. 
RESEARCH AIM 4: COMPLEMENTARY AND ALTERNATIVE MEDICINE  
Prior studies have shown that 50-80% of midlife women have utilized some type 
of CAM. (Bair, et al., 2005; Bair, et al., 2002; Factor-Litvak, et al., 2001; Kaufert, et al., 
Utian, 1998; Kronenberg & Fugh-Berman, 2002). These studies illustrated that many 
different cultural groups of women adopt CAM, yet women of lower socioeconomic 
status are less likely to use CAM.  
Consistent with prior studies, the current study found that nearly half of the 
women reported the use of an alternative treatment to treat vasomotor symptoms. Women 
who were between the ages of 40-50, less than 5 years post menopause onset, and those 
who experienced medical menopause were more likely to utilize alternative treatments 
(see table 1).  Although it is known that CAM therapies can be expensive, the current 
study did not find educational level or income to be a factor in the adoption of CAM.  
The most common choices of CAM modalities were botanicals such as 
multivitamins and calcium, Black Cohosh and Soy supplements and/or soy foods. Other 
more commonly chosen CAM methods included meditation and relaxation. Although 
early research is beginning to emerge with regard to the usefulness and safety of 
alternative medical systems such as homeopathy, acupuncture, and TCM very few 
women listed these as an option that they had utilized.   
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Many women reported the use of antidepressants specifically taken to relieve 
vasomotor symptoms. In fact, those who utilized antidepressants perceived them to be 
one of the most efficacious methods. There were only 8 alternative therapies that were 
used by at least 30 women (multivitamins and calcium, Black Cohosh, Soy supplements 
and food, antidepressants, meditation and relaxation, evening primrose oil, Homeopathy 
and blood pressure medications). Given the vast amount of alternatives that can be used, 
and the small numbers for each method, it not possible to discern what is the most 
effective method. Further studies are needed in this area.  
VALIDATION OF THE MODEL 
The study findings support the usefulness of Bronfenbrenner’s ecological theory 
as a model to view the vasomotor experiences of menopausal women who have 
discontinued HT. This study showed that there are many factors that influencing the 
occurrence of vasomotor symptoms after discontinuation HT. 
Macrosystems are broad cultural and historical influences (Bronfenbrenner, 1979) 
which were operationalized for this study as pivotal clinical trials influencing menopause 
symptom management modalities (i.e.: HERS I & II and WHI) and the subsequent 
consensus statements from different organizations. The consensus statements provided 
evidence based clinical practice guidelines for health care providers who care for women.  
The findings in this study illustrated that indeed over 40% of the women reported that 
they discontinued HT because of clinical information that they had personally read, heard 
on the television or obtained from the internet. Additionally, women reported that they 
stopped HT based on their health care provider’s recommendations. These findings 
indicate that these macrosystems do influence their decisions.  
Mesosystems as described earlier are those settings in which the individual 
interacts in more than one setting either alone or through linkage of a third party. The 
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mesosystem and exosystems were operationalized in this study as the influences of 
friends, family or health care providers with regard to the menopause experience and 
management strategies for vasomotor symptoms.  Thirty three percent of the participants 
discontinued HT because their health care provider recommended that they do so. Many 
women also stopped on the recommendations of their family, friends, coworkers and 
even pharmacists demonstrating that mesosystems also contributed to their decisions to 
stop HT. 
Microsystems consist of an individual’s genetic make up (ethnicity, race, age at 
menopause), personal characteristics (weight, height, general health, smoking, alcohol or 
drug use). Microsystems were operationalized in this study as the individual contextual 
factors previously identified (Research aim 1). As validated by the logistic regression 
model, some of the contextual factors played a significant role in the occurrence of 
vasomotor symptoms post discontinuation of HT.  
Over a third of the women in this study used some type of alternative medical, or 
CAM therapy to treat their symptoms after discontinuation of HT. As more women seek 
out other alternatives for the relief of vasomotor symptoms, there will be an increase 
demand by women and clinicians for high level evidenced based clinical information 
about the safety and efficacy of these alternatives.  
In response there is an increasing amount of studies designed to look the safety 
and efficacy of CAM methods such as acupuncture are appearing in the literature (Huang, 
et al., 2006), homeopathy (Jacobs, Herman, Heron, Olsen, & Vaughters, 2005), 
Aryuvedic (Saper, et al., 2004), biofeedback and relaxation (Nestrand, et al., 2005), and 
soy (Lewis, Nickell, Thompson, Szalai, Kiss, et al, 2006).  In addition, various related 
clinical trials are in progress. Of 163 menopausal related clinical trials registered at 
http://www.clinicaltrials.gov/, 35 were investigating non-hormonal methods to reduce hot 
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flashes. Of these studies, there was one with homeopathy, two with mindful meditation 
and breathing, two new trials investigating the use of TCM herbs and at least two 
additional trials are underway with acupuncture. Biological agents being studied are 
DHEA and soy. One study is investigating the use of yoga for the treatment of hot 
flashes.  Although there have been lay texts and websites indicating that yoga may be 
effective in reducing vasomotor symptoms, there were no randomized controlled trials 
that have been published testing yoga.  The interest in these methods and new trials 
ensuing is very exciting for women and health care providers alike.  
In the present study, women reported antidepressants were one of the most 
efficacious methods for treating vasomotor symptoms. Antidepressants are also 
increasingly included in clinical trials (Evans, et al., 2005). Emerging clinical trials are 
being designed to explore alternative doses of previously approved antidepressants 
tailored specifically for the treatment of hot flashes such a mirtazapine (Remeron®). 
Mirtazapine is classified as a noradrenergic and specific serotonergic antidepressant 
(Perez, et al., 2004). In addition, several studies are evaluating the effectiveness of the 
antiseizure medication, gabapentine with the most recent in 2006 (Reddy, et al., 2006). In 
fact, the pharmaceutical company, Depomed, Inc, has recently submitted an 
Investigational New Drug (IND) application with the U.S. Food and Drug Administration 
(FDA) for Gabapentin GR(TM) for the treatment of postmenopausal hot flashes.  
In summary, Bronfenbrenner (1979) asserts that the ecological framework of 
human development involves the interaction of the individual, changes in their immediate 
environment as well as a larger environment beyond the immediate environment within 
which the individual is located. The individual is not a fixed entity within the 
environment, but is a dynamic force that has impact on the environment within which the 
individual resides as well. Clearly the literature and the findings of this study have 
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illustrated this concept. The influence of pivotal trails and consensus statements has had 
an impact on health care provider practice patterns and women’s decisions to discontinue 
HT earlier and possible abruptly. The appearance of vasomotor symptoms after 
discontinuation has resulted in the adoption of alternative methodologies to treat 
continuing vasomotor symptoms. With the increase in use of these therapies there is an 
increase demand for high level studies on safety and efficacy of these methods.  
LIMITATIONS 
The sample size for this study was adequate in numbers for the statistical tests 
used.  However, it was nonprobablity convenience sample drawn from mailing list of 
which there was limited knowledge about the group of women. The sample does not 
include an adequate sample from each state, although the participants were fairly equally 
distributed throughout the 4 US census geographical regions. The sample was 
predominantly White and while it does not actually reflect the ethically and racial diverse 
US population it does reflect the population of women who typically use HT (Brennan, 
Crespo& Wactawski-Wende, 2004). 
Generalizability of this study is limited and is dependent upon the depth and 
breadth of the population sample that was gathered. Findings only reflect those women 
who have taken a break from or discontinued hormone therapy and cannot be generalized 
to women who continue HT. To avoid selection bias every effort has been made to gather 
participants from various venues (doctor’s offices, health clubs, malls, grocery stores, and 
churches). In addition, a variety of advertisements (word of mouth, written ads, flyers, 
business cards) were used to ensure that as many women as possible will be reached 
throughout the various regions of the US.  Despite the efforts to attract a diverse 
population of women, the sample does not represent all women in the United States 
particularly with regard to race and socioeconomic status. 
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Recall bias is also a limitation of this study as a majority of the participants were 
well past menopause onset. Participants were asked to complete a questionnaire that 
reflected incidents that happened in the past. It is known that an individual’s ability to 
recall the past is limited and recall bias can make the information less reliable. Although 
recall bias was considered important, in order to recruit an adequate sample, no restraints 
were placed on length of time since hormones were discontinued.  
The questionnaire developed for this study was piloted in a group of 10 women in 
order to assess any biases within the format of the questions. From the pilot group 
responses there did not appear to be any questions that were ambiguous or leading. The 
participants reported that the terms with the exception of Aryuvedic medicine and 
Homeopathy were clear and familiar to them. The small sample size and lack of diversity 
of the participants of the pilot is another limitation with regard to questionnaire 
development.  
There is no clear biological marker for menopause therefore the diagnosis of 
natural menopause is made retrospectively after 12 consecutive months of amenorrhea, 
for which there is no other obvious pathological or physiological cause (CAMS, 2004). 
This retrospective nature of diagnosing menopause can be very confusing for women. In 
this study women were not given a specific definition for menopause and were self 
selected and using their own judgment regarding their menopausal status. Purposeful 
sampling of women who were over the age of 40 and had been prescribed HT from a 
health care provider for menopause may have helped to avoid recruitment of women who 
were not menopausal. 
In summary although biases and limitations exist, this study was an exploratory 
study designed to assess trends and characteristics of women who have discontinued HT.  
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The findings have generated additional descriptive data that will provide a platform for 
future prospective studies.  
IMPLICATIONS AND RECOMMENDATIONS 
The results of this study suggest that a majority of menopausal women experience 
vasomotor symptoms after discontinuation of HT. Guided by an ecological framework 
this study identified contextual factors that were significantly associated with the 
occurrence of vasomotor symptoms after discontinuation of HT.  This knowledge plays 
an integral part in helping health care providers to identify women who may find it more 
difficult to discontinue HT so that they can be appropriately counseled and assisted 
through the transition of withdrawing from hormones.  
In this study, a small number of women restarted HT because of the vasomotor 
symptoms. It is important for health care providers to be aware that despite the 
recommendations for a shortened duration of HT there will be women who do not want 
to discontinue or desire to restart HT after a difficult discontinuation. Data also showed 
that many women do intend to make informed choices by gathering information for 
themselves as well as from their health care provider. This illustrates the importance of 
individualizing care, discussing the benefits and risks at a level that is appropriate the 
individual’s health literacy level. Women should have the opportunity to weigh the 
benefits, risks and adverse events for themselves.  
Nearly a third of the women opted to try an alternative medical or CAM therapy 
to manage vasomotor symptoms. This study provides an early glimpse into what types of 
CAM that women accept, use and perceive as helpful. As discussed earlier, the North 
American Menopause Society (NAMS) recommends that for women who are 
experiencing only mild vasomotor symptoms that a medical alternative or 
nonprescription CAM methods should be offered despite the lack of evidence to support 
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the effectiveness of these methods. (NAMS, 2004). Given these recommendations there 
will likely be an increase in the use of these modalities. From an ecological standpoint, 
not only are more randomized clinical trials needed to evaluate the safety and efficacy of 
these alternative methods, there is also a need for exploratory studies to look acceptance 
as well as possible cultural or socioeconomic barriers to their use. 
Many of these emerging therapies such as over the counter botanicals, 
acupuncture, meditation, and yoga classes can be costly and may not be available in some 
areas or to all women.  This opens up opportunities for the establishment of sustainable 
community based programs that can offer low or no cost CAM methodologies for 
menopausal women who may not have the resources or availability of these modalities in 
their areas. In addition, there is a need for community based awareness programs to 
educate women about menopause, HT, and the available alternatives for treatment of 
vasomotor symptoms.  
Although this study has shown there are significant relationships between some 
contextual factors and the occurrence of vasomotor symptoms, they explain only small 
part of the variation of symptom experiences between women.  There is a need for further 
studies investigating other emerging etiologic factors related to vasomotor symptoms 
such as diminished glucose availability (Dormire & Reame, 2003). 
CONCLUSION 
This study contributes to the literature on HT discontinuation experiences of 
menopausal women. What is unique about this study is that although it was not a 
population based sample and was not ethically or racially diverse, it was able to capture 
data from a group of menopausal women with a lower educational and income status that 
are not  usually included in menopause and HT related studies.  
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The current study findings reveal that a large majority of menopausal women who 
were previously taking HT do experience vasomotor symptoms after discontinuation. 
These findings are consistent with other recent discontinuation studies (Grady, et al, 
2003; Ockene, et al, 2005). The most common predictors of the occurrence of vasomotor 
symptoms were younger age, type of menopause and the occurrence of vasomotor 
symptoms prior to initiation of HT. 
These study findings have also shown that many women undertook some type of 
alternative medical, or CAM therapy to treat their vasomotor symptoms after 
discontinuation of HT. As more women seek out other alternatives for the relief of 
vasomotor symptoms, there is an increase demand by women and clinicians for high level 
evidenced based clinical information about the safety and efficacy of these alternatives. I 
Finally, the study findings clearly support the usefulness of an adaptation of 
Bronfenbrenner’s ecological theory as a model through which to view the vasomotor 
experiences of menopausal women who have discontinued HT. This study showed that 
there are many factors influencing the decision to discontinue HT.  Individual contextual 
factors were also identified that are associated with occurrence of vasomotor symptoms 
after discontinuation. Through this framework, this study opens up many opportunities 
for further studies in the areas of vasomotor treatment modalities safety and efficacy, 
exploration of women’s acceptance of these new methods as well as the development of 




APPENDIX 1: QUESTIONNAIRE 
COVER LETTER INTRODUCTION 
Thank you for your interest in participating in this study.  I am exploring the experiences of menopausal women who have taken prescription 
hormones (estrogen or estrogen plus progesterone) for menopause, but have either taken a break from or stopped taking them all together. Women 
who participate in this study should be over the age of 40, have previously been on “prescription” hormones (estrogen, progesterone or 
testosterone) for menopause, have taken that prescription for at least 3 months consistently, then have either taken a break from or stopped taking 
the hormones completely.    
No information identifying you as an individual will be collected; therefore a consent form is not necessary. Below you will find an written overview 
of this study. Your completion and return of the questionnaire will be all that is needed to indicate your willingness to participate.  Your name, 
address, and telephone number and/or email address will only be used to contact you initially to mail or email the questionnaire to you.  The 
questionnaire will have an identification number but your personal information will not be connected in any way to that number.  To provide 
anonymity your name, address, and telephone number will be shredded/deleted after the questionnaire is sent to you. 
To participate in the study, please complete the attached questionnaire and return it via email at EMKupferer@aol.com or via postal mail in the 
supplied preaddressed and stamped envelope to: 
Principal Investigator:                                                           
Elizabeth M. Kupferer MSN, RN-C                                           
Women’s Health Care Nurse Practitioner                                 
Doctoral Candidate, School of Nursing University of Texas, Austin TX                                               
2511 Trimmier Road, Suite 140, PMB 347                                                                             
Killeen, TX 76542       Toll free number: 1-866-224-1161 
I sincerely thank you for contributing your information to this exploratory study.  Your time and effort will help to gain more knowledge about 
women’s experiences with hormone therapy during these perplexing times of conflicting information with regard to hormone therapy use. 
Sincerely, 
Elizabeth M. Kupferer 
Study Overview 
Title of Research Study:   “An exploration of Women’s current Hormone discontinuation experiences, influences, decisions, and alternatives 
Principal Investigator:                                                        Faculty Sponsor: 
Elizabeth M. Kupferer MSN, RN-C                                          Sharon Dormire, PhD, RN 
Women’s Health Care Nurse Practitioner                                Assistant Professor 
Doctoral Candidate, School of Nursing                                   School of Nursing 
University of Texas, Austin TX                                              University of Texas, Austin TX 
2511 Trimmier Road, Suite 140                                            1700 Red River Street 
PMB 347                                                                            Austin, TX 78701-1499 
Killeen, TX 76542                                                                Campus Mail Code: DO100 
512-567-6117 or 254-939-3318                                            512-471-7944 
Funding source: No outside funding sources 
What is the purpose of the study? 
The primary goal of this project is explore the experiences of women who have discontinued hormone therapy as well as to investigate factors have 
influenced discontinuation. In addition, we will look at the use of alternative treatments and their perceived efficacy. 
What is next if you decide to take part in this research study? 
If you have received this study packet and are interested in participating you only need to review this document, read the cover letter, complete the 
questionnaire then return the questionnaire either via Email to EMKupferer@aol.com or return via postal mail in the supplied preaddressed, 
stamped envelope to the address listed above. Your consent to participate in this study will be noted by the completion and return of the 
questionnaire with your comments, no signature is necessary.  
What are the possible discomforts and risks? 
Your participation should not impose any psychological, social or legal risks to the participants. Potential drawbacks might include your being 
inconvenienced because of the time spent filling out the survey and returning them via mail. If you are upset by any of the questions please feel 
free to stop the survey. If you have any questions or comments please do not hesitated to contact Elizabeth Kupferer. 
What are the potential benefits to you or others? 
Although you will not likely directly benefit from participation in the study, but you will potentially benefit other menopausal women by allowing the 
researcher to gain insight regarding yours and other women’s hormone discontinuation experiences.  In addition, if you would like to be notified of 
the study results when completed, you should send an email to Elizabeth Kupferer at EMKupferer@aol.com to be added to a distribution list that will 
only be used for notification of the study results. 
If you choose to take part in this study, will it cost you anything? 
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There will be no cost to you for being in this study.  
Will you receive compensation for your participation in this study?  
There is no compensation for your participation 
What if you are injured because of the study? 
No injury would result from the completion of a questionnaire. 
If you do not want to take part in this study, what other options are available to you? 
Participation in this study is entirely voluntary. It is entirely up to you if you want to participate in the study. You are free to refuse to be in the study 
by simply not filling out the questionnaire. If you decline to participate it will not influence current or future relationships with The University of 
Texas at Austin.  
How can you withdraw from this research study and who should I call if I have questions? 
If you do not wish to participate, simple discard the materials. You are free to withdraw your consent at any time without penalty or loss of benefits. 
If you have any additional questions about your rights as a research participant, please contact Lisa Leiden, PhD, Chair, The University of Texas at 
Austin Institutional Review Board for the Protection of Human Subjects at 512-232-4381. 
How will your privacy and the confidentiality of your research records be protected? 
Authorized persons from the University of Texas at Austin and Institutional Review Board have the legal right to review research records and will 
protect the confidentiality of those records to the extent permitted by law. Your research records will not be released without your consent unless 
required by law or court order. If the results of this research are published or presented at a scientific meeting your identity will NOT be disclosed. 
No names will be used on the surveys. ID numbers have been assigned to each individual questionnaire that is NOT linked to the actual participant. 
All identifying information will be deleted and/or shredded and will not be kept by the researcher. Access to the questionnaire is only allowed to the 
principal investigator, Elizabeth Kupferer. 
Will the researcher benefit form your participation in this study? 
Completion of this study will contribute to meeting doctoral degree requirements for the Elizabeth Kupferer, the principal investigator. 
ELIGIBILITY CRITERIA 
Are you menopausal? Have you gone through menopause? 
Are you over the age of 40? 
Have taken “prescription” for hormone therapy (i.e.: estrogen) for menopause previously? 
Did you take those hormones consistently for at least 3 months in row? 
Have you stopped or taken a break from prescription hormones? 
Are you willing to complete and return the questionnaire via mail or email? 
Yes   No 
Yes   No 
Yes   No 
Yes   No 
Yes   No 
Yes   No 
HORMONE DISCONTINUATION QUESTIONNAIRE 
ID#       (for office use only) Birth date:      /       Age:               
Where do you live? City:                                    State:        
Ethnicity/Race:     Asian    Black      Hispanic     White     Other (list)            
Marital status:    Single    Partnered      Married      Separated      Divorced      Widowed 
Education: Some high school  General Education Degree (GED)  High school diploma   Some college  Associate Degree  Bachelors Degree  Masters Degree  Doctoral Degree 
Income: <$10,000  $10,001-$20,000  $20,001-$30,000  $30,001-$40,000  $40,001-$50,000   $50,001-$60,000  $60,001-$70,000  $70,001-$80,000  $80,001-$90,000 $90,001-$100,000 >$100,001 
What is your height: _____ feet   _____ inches What is your weight:        pounds 
MENOPAUSE HISTORY 
At what age or what year did you go 
through menopause? 
Age:                  or                  Year:      
What type of menopause?  Natural    Surgical (hysterectomy with removal of ovaries)    Medical (i.e.: cancer treatments) 
When did you begin hormone therapy? Age:                  or                   Year:      
Why was hormone therapy prescribed 
for you? 
(check all that apply) 
 To treat hot flashes/night sweats 
 To treat other menopausal symptoms 
 To treat/reduce vaginal dryness 
 To treat bladder or urinary problems 
 I am not sure why 
 To reduce risk for heart disease 
 To reduce risk of osteoporosis 
 To reduce risk of colon cancer 
 Other (please list):                        
 
Did you have hot flashes before you 
started hormone therapy?  Yes    No 
Did you have night sweats before you 
started hormone therapy?  Yes   No 
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HORMONE THERAPY DECISION INFLUENCES 
When did you discontinue hormone therapy? Month:                        Year:        
How did you discontinue hormone therapy?  Stopped suddenly        Weaned off slowly  
What type of hormone therapy were you on 
prior to stopping? Premarin®(conjugated equine estrogen: [CEE]) 









 Vivelle®,Climara®, Estraderm®, 
Alora®, Esclim® (estrogen only patch) 
Combipatch® (estradiol/norethindrone 
acetate) 
FemRing® (vaginal ring) 
Estring® vaginal ring or 
Premarin®/Estrace® vaginal creams (local 
estrogens) 
Estratab®/Menest®(Esterifed estrogen) 
Estratest® (estrogen with testosterone) 





Other (please list):      
What influenced your decision to stop taking 
hormone therapy? 















Side effects (bloating, 
headache, bleeding) 
 
Serious life threatening side 
effect (stroke, cancer, blood 
clot) 
 
Health care provider 
recommended without a 
specific reason 
 
Health care provider 
recommended because of  
current health conditions such 
has high blood pressure, 
cardiovascular disease or 
other illnesses 
Your husband or life partner 
recommended that you should 
stop A friend or co-worker 
recommended that you stop 
 
Your pharmacist 
recommended that you stop 
 
Stopped  because of the 
cost of your prescription 
 
Stopped on your own 
because of recent information 
obtained from: 
internet  
written publication  
television ad  
Please list what that  info was 
about: 
To try another type of 
treatment 
 
Afraid of increased 
breast cancer risk 
 
Afraid of blood clot or 
stroke 
 
No particular reason, 
you just decided to stop 
on your own 
 
Stopped on own, 
wanted to see how you 
would feel off hormones 
Other (please list): 
Are you familiar with a study called the 
Women’s Health Initiative (WHI)?  Yes    No  
Did the study findings influence your decision 
to stop hormone therapy?  Yes    No   I am not familiar with this study 
DISCONTINUATION EXPERIENCES 
Did you experience hot flashes after you 
stopped hormone therapy? No     Yes: How many per day?      How severe?    Mild   Moderate  Severe  
Did you experience night sweats after you 
stopped hormone therapy? No     Yes: How many per day?       How severe?    Mild   Moderate  Severe  
Have your hot flashes resolved without 
restarting hormone therapy or alternative 
treatments? 
No     Yes: Resolved within _____ months or ______days of stopping 
Are you still experiencing hot flashes? No     Yes: How many per day?      How severe?    Mild   Moderate  Severe  
Are you still experiencing night sweats? No     Yes: How many per day?         How severe?   Mild   Moderate  Severe 
Have you restarted hormone therapy? No     Yes  
Did you restart hormone therapy because of 
hot flashes? No     Yes: Are hot flashes/night sweats now resolved?     No   Yes  Partially 
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If you have not restarted hormone therapy, 
will you? No     Yes     Not sure   Awaiting more information 
Have you used other alternative therapies or 
medications to treat hot flashes or night 
sweats? 
No     Yes (if you answered yes to the use of alternatives to treat your hot flashes or 
night sweats please complete the next section “Alternative menopause treatments used to 
treat hot flashes or night sweats”) 
ALTERNATIVE MENOPAUSE TREATMENTS USED TO TREAT HOT FLASHES OR NIGHT SWEATS 
ALTERNATIVE MEDICINE SYSTEMS 
Acupuncture   Yes   No                                 Helped   Did not help   Not sure 
Ayurveda   Yes   No                                 Helped   Did not help   Not sure 
Homeopathy   Yes   No                                 Helped   Did not help   Not sure 
Traditional Chinese Medicine (TCM)   Yes   No                                 Helped   Did not help   Not sure 
BIOLOGICALLY BASED THERAPIES (DIETARY SUPPLEMENTS) 
Black Cohosh   Yes   No                                 Helped   Did not help   Not sure 
Evening primrose oil   Yes   No                                 Helped   Did not help   Not sure 
Soy   Yes   No                                 Helped   Did not help   Not sure 
Red clover   Yes   No                                 Helped   Did not help   Not sure 
Vitamins/Calcium   Yes   No                                 Helped   Did not help   Not sure 
Bio-identical hormones    Yes   No                                 Helped   Did not help   Not sure 
Other (list)         Yes   No                                 Helped   Did not help   Not sure 
MIND BODY METHODS 
Meditation/Relaxation   Yes   No                                 Helped   Did not help   Not sure 
Yoga   Yes   No                                 Helped   Did not help   Not sure 
OTHER MEDICAL TREATMENTS 
Prescription antidepressants (Prozac, Effexor, 
Paxil)   Yes   No                                 Helped   Did not help   Not sure 
Prescription antiseizure medication 
(Neurontin [gabapentine])   Yes   No                                 Helped   Did not help   Not sure 
Prescription blood pressure medication 
(Clonidine) 
  Yes   No                                 Helped   Did not help   Not sure 
 
HEALTH HABITS 
Exercise  No exercise 
  Mild exercise (i.e., climb stairs, walk 3 blocks, golf) 
 Occasional vigorous exercise (i.e., work or recreation, less than 4x/week for 30 min.) 
  Regular vigorous exercise (i.e., work or recreation 4x/week for 30 minutes) 
Alcohol Do you drink alcohol?  Yes   No      If yes, what kind?  wine beer liquor     How many drinks per week?  ______ 
Tobacco Do smoke cigarettes?   Yes   No               How many packs per day? ______       How long have you smoked?       years 
The questionnaire is complete 
Thank you for participating 
Please return the questionnaire in the enclosed preaddressed stamped envelope or via email to EMKupferer@aol.com 
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